Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
(10bR)-8-chloro-4,10b-dimethyl-1,4,6,10b-tetrahydrobenzo[f]quinoline-3(2H)-thione
13.2% inhibition at 0.04 mM
(10bR)-8-chloro-4,10b-dimethyl-1,5,6,10b-tetrahydrophenanthridin-3(2H)-one
-
(10bR)-8-chloro-4,5,10b-trimethyl-1,5,6,10b-tetrahydrophenanthridin-3(2H)-one
-
(10bR)-8-chloro-5,10b-dimethyl-1,5,6,10b-tetrahydrophenanthridin-3(2H)-one
-
(11aR)-7-(1-hydroxypropan-2-yl)-1,4a,6a-trimethylhexadecahydro-2H-indeno[5,4-f]quinolin-2-one
weak inhibition; weak inhibition
(11aR)-7-(1-hydroxypropan-2-yl)-1,4a,6a-trimethyltetradecahydrocyclopenta[5,6]naphtho[2,1-d][1,3]oxazin-2(1H)-one
weak inhibition; weak inhibition
(11aR)-7-(1-hydroxypropan-2-yl)-1,4a,6a-trimethyltetradecahydrocyclopenta[5,6]naphtho[2,1-d][1,3]oxazine-2(1H)-thione
weak inhibition; weak inhibition
(11aR)-N,N-diethyl-1,4a,6a-trimethyl-2-oxohexadecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
weak inhibition; weak inhibition
(16alpha,17beta)-17-hydroxy-16-methylandrost-4-en-3-one
(16beta)-16-bromo-3,20-dioxopregna-1,4,6-trien-17-yl cyclopentylacetate
-
(16beta)-16-methyl-3,20-dioxopregna-1,4,6-trien-17-yl acetate
-
(16beta)-16-methyl-3,20-dioxopregna-1,4,6-trien-17-yl cyclopentylacetate
-
(16beta)-16-methyl-3,20-dioxopregna-1,4,6-trien-17-yl pentanoate
-
(16beta)-16-methyl-3,20-dioxopregna-4,6-dien-17-yl acetate
-
-
(16beta)-16-methyl-3,20-dioxopregna-4,6-dien-17-yl butanoate
-
-
(16beta)-16-methyl-3,20-dioxopregna-4,6-dien-17-yl cyclopentylacetate
-
(16beta)-16-methyl-3,20-dioxopregna-4,6-dien-17-yl cyclopropanecarboxylate
-
(16beta)-16-methyl-3,20-dioxopregna-4,6-dien-17-yl pentanoate
-
-
(16beta)-16-methyl-3,20-dioxopregna-4,6-dien-17-yl phenylacetate
-
-
(16beta)-16-methylandrost-4-ene-3,17-dione
(16beta)-17-hydroxy-16-methylpregna-1,4,6-triene-3,20-dione
-
(16beta)-6-bromo-16-methyl-3,20-dioxopregna-4,6-dien-17-yl acetate
-
(16beta)-6-bromo-17-(hex-1-en-2-yloxy)-16-methylpregna-4,6-diene-3,20-dione
-
(16beta)-6-chloro-16-methyl-17-[(1-phenylethenyl)oxy]pregna-4,6-diene-3,20-dione
-
(16beta)-6-chloro-16-methyl-3,20-dioxopregna-4,6-dien-17-yl acetate
-
(17beta)-16-ethyl-17-hydroxyandrost-4-en-3-one
(17beta)-17-(2-oxo-3-phenyl-1,3-oxazinan-6-yl)androst-4-en-3-one
-
-
(17beta)-17-(2-oxo-3-phenyl-1,3-oxazinan-6-yl)androst-4-en-3-one - 3-phenyl-1,3-oxazinan-2-one (1:1)
-
(17beta)-17-(propan-2-ylcarbamoyl)estra-1(10),2,4,6,8-pentaene-3-carboxylic acid
-
(17beta)-17-(propan-2-ylcarbamoyl)estra-1(10),2,4,6-tetraene-3-carboxylic acid
-
(17beta)-17-(propan-2-ylcarbamoyl)estra-1(10),2,4-triene-3-carboxylic acid
-
(17beta)-17-(propan-2-ylcarbamoyl)estra-1,3,5(10)-triene-3-sulfonic acid
-
(17beta)-17-[(5S)-2-(2-chlorophenyl)-4,5-dihydro-1,3-oxazol-5-yl]androst-4-en-3-one
-
-
(17beta)-17-[(5S)-2-(4-bromophenyl)-4,5-dihydro-1,3-oxazol-5-yl]androst-4-en-3-one
-
-
(17beta)-17-[(5S)-2-(4-chlorophenyl)-4,5-dihydro-1,3-oxazol-5-yl]androst-4-en-3-one
-
-
(17beta)-17-[(5S)-2-(4-fluorophenyl)-4,5-dihydro-1,3-oxazol-5-yl]androst-4-en-3-one
-
-
(17beta)-17-[(5S)-2-(4-nitrophenyl)-4,5-dihydro-1,3-oxazol-5-yl]androst-4-en-3-one
-
-
(17beta)-17-[(5S)-2-phenyl-4,5-dihydro-1,3-oxazol-5-yl]androst-4-en-3-one
-
-
(17beta)-17-[3-(4-bromophenyl)-2-oxo-1,3-oxazinan-6-yl]androst-4-en-3-one
(17beta)-17-[3-(4-chlorophenyl)-2-oxo-1,3-oxazinan-6-yl]androst-4-en-3-one
(17beta)-17-[3-(4-ethoxyphenyl)-2-oxo-1,3-oxazinan-6-yl]androst-4-en-3-one
(17beta)-17-[3-(4-ethylphenyl)-2-oxo-1,3-oxazinan-6-yl]androst-4-en-3-one
(17beta)-17-[3-(4-methoxyphenyl)-2-oxo-1,3-oxazinan-6-yl]androst-4-en-3-one
(17beta)-17-[di(propan-2-yl)carbamoyl]-4-fluoroandrost-3-ene-3-carboxylic acid
-
(17beta)-17-[di(propan-2-yl)carbamoyl]-4-methylandrosta-3,5-diene-3-carboxylic acid
-
(17beta)-17-[di(propan-2-yl)carbamoyl]-6-fluoroandrosta-3,5-diene-3-carboxylic acid
-
(17beta)-17-[di(propan-2-yl)carbamoyl]androst-3-ene-3-carboxylic acid
-
(17beta)-17-[di(propan-2-yl)carbamoyl]androsta-2,4,6-triene-3-carboxylic acid
-
(17beta)-17-[di(propan-2-yl)carbamoyl]androsta-3,5,11-triene-3-carboxylic acid
-
(17beta)-17-[di(propan-2-yl)carbamoyl]androsta-3,5-diene-3-carboxylic acid
-
(17beta)-17-[di(propan-2-yl)carbamoyl]estra-3,5-diene-3-carboxylic acid
-
(17beta)-2-chloro-17-(propan-2-ylcarbamoyl)estra-1(10),2,4-triene-3-carboxylic acid
-
(17beta)-3-(hydroxymethyl)-N-(propan-2-yl)androsta-3,5-diene-17-carboxamide
(17beta)-3-nitro-N-(propan-2-yl)androst-3-ene-17-carboxamide
-
(17beta)-4-bromo-N-tert-butyl-3-oxoandrost-4-ene-17-carboxamide
-
(17beta)-4-fluoro-17-(propan-2-ylcarbamoyl)estra-1(10),2,4-triene-3-carboxylic acid
-
(17beta)-N-tert-butyl-3-oxo-4-sulfanylandrost-4-ene-17-carboxamide
-
(17beta)-N-tert-butyl-4-chloro-3-oxoandrost-4-ene-17-carboxamide
-
(17beta)-N-tert-butyl-4-cyano-3-oxoandrost-4-ene-17-carboxamide
-
(1R,4R,9aR,11aR)-4,9a,11a-trimethyl-1-((R)-6-methylheptan-2-yl)-3,3a,3b,4,5,8,9,9a,9b,10,11,11a-dodecahydro-1H-cyclopenta[i]phenanthridin-7(2H)-one
-
(1R,4S,9aR,11aR)-4,9a,11a-trimethyl-1-((R)-6-methylheptan-2-yl)-3,3a,3b,4,5,8,9,9a,9b,10,11,11a-dodecahydro-1H-cyclopenta[i]phenanthridin-7(2H)-one
-
(1R,9aR,11aR)-9a,11a-dimethyl-1-((R)-6-methylheptan-2-yl)-3,3a,3b,4,5,8,9,9a,9b,10,11,11a-dodecahydro-1H-cyclopenta[i]phenanthridin-7(2H)-one
-
(1S,8bS,10aS)-N,N-diethyl-8b,10a-dimethyl-7-oxo-1,2,3,3a,3b,4,5,7,7a,8,8a,8b,8c,9,10,10a-hexadecahydrocyclopenta[i]cyclopropa[a]phenanthridine-1-carboxamide
-
(1S,9aR,11aR)-1-butyl-9a,11a-dimethyl-1,2,3,3a,3b,4,5,8,9,9a,9b,10,11,11a-tetradecahydro-7H-cyclopenta[i]phenanthridin-7-one
-
(1S,9aR,11aS)-1-(cyclohexylacetyl)-9a,11a-dimethyl-1,2,3,3a,3b,4,5,8,9,9a,9b,10,11,11a-tetradecahydro-7H-cyclopenta[i]phenanthridin-7-one
-
(1S,9aR,11aS)-6-bromo-9a,11a-dimethyl-7-oxo-N-(tricyclo[3.3.1.13,7]dec-1-yl)-2,3,3a,3b,4,5,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-cyclopenta[i]phenanthridine-1-carboxamide
-
(1S,9aR,11aS)-6-bromo-N,N-diethyl-9a,11a-dimethyl-7-oxo-2,3,3a,3b,4,5,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-cyclopenta[i]phenanthridine-1-carboxamide
-
(1S,9aR,11aS)-6-chloro-9a,11a-dimethyl-7-oxo-2,3,3a,3b,4,5,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-cyclopenta[i]phenanthridine-1-carboxamide
-
(1S,9aR,11aS)-6-chloro-N,N-diethyl-9a,11a-dimethyl-7-oxo-2,3,3a,3b,4,5,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-cyclopenta[i]phenanthridine-1-carboxamide
-
(1S,9aR,11aS)-9a,11a-dimethyl-1-nonanoyl-1,2,3,3a,3b,4,5,8,9,9a,9b,10,11,11a-tetradecahydro-7H-cyclopenta[i]phenanthridin-7-one
-
(1S,9aR,11aS)-9a,11a-dimethyl-N-(2-methylpropyl)-7-oxo-2,3,3a,3b,4,5,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-cyclopenta[i]phenanthridine-1-carboxamide
-
(1S,9aR,11aS)-N,N-diethyl-5,9a,11a-trimethyl-7-oxo-2,3,3a,3b,4,5,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-cyclopenta[i]phenanthridine-1-carboxamide
-
(1S,9aR,11aS)-N,N-diethyl-5,9a,11a-trimethyl-7-oxo-2,3,3a,3b,4,5,7,9a,9b,10,11,11a-dodecahydro-1H-cyclopenta[i]phenanthridine-1-carboxamide
-
(1S,9aR,11aS)-N,N-diethyl-6,9a,11a-trimethyl-7-oxo-2,3,3a,3b,4,5,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-cyclopenta[i]phenanthridine-1-carboxamide
-
(1S,9aR,11aS)-N,N-diethyl-9a,11a-dimethyl-7-oxo-2,3,3a,3b,4,5,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-cyclopenta[i]phenanthridine-1-carboxamide
-
(1S,9aR,11aS)-N-(4,4'-di-tert-butylbiphenyl-3-yl)-9a,11a-dimethyl-7-oxo-2,3,3a,3b,4,5,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-cyclopenta[i]phenanthridine-1-carboxamide
-
(1S,9aR,11aS)-N-(4-tert-butylbiphenyl-3-yl)-9a,11a-dimethyl-7-oxo-2,3,3a,3b,4,5,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-cyclopenta[i]phenanthridine-1-carboxamide
-
(1S,9aR,11aS)-N-(5-bromo-2-tert-butylphenyl)-9a,11a-dimethyl-7-oxo-2,3,3a,3b,4,5,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-cyclopenta[i]phenanthridine-1-carboxamide
-
(1S,9aR,11aS)-N-(dicyclohexylmethyl)-9a,11a-dimethyl-7-oxo-2,3,3a,3b,4,5,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-cyclopenta[i]phenanthridine-1-carboxamide
-
(1S,9aR,11aS)-N-(diphenylmethyl)-6,9a,11a-trimethyl-7-oxo-2,3,3a,3b,4,5,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-cyclopenta[i]phenanthridine-1-carboxamide
-
(1S,9aR,11aS)-N-(diphenylmethyl)-9a,11a-dimethyl-7-oxo-2,3,3a,3b,4,5,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-cyclopenta[i]phenanthridine-1-carboxamide
-
(1S,9aR,11aS)-N-tert-butyl-6,9a,11a-trimethyl-7-oxo-2,3,3a,3b,4,5,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-cyclopenta[i]phenanthridine-1-carboxamide
-
(1S,9aR,11aS)-N-[1-(4-chlorophenyl)cyclobutyl]-9a,11a-dimethyl-7-oxo-2,3,3a,3b,4,5,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-cyclopenta[i]phenanthridine-1-carboxamide
-
(1S,9aR,11aS)-N-[2,5-bis(trifluoromethyl)phenyl]-9a,11a-dimethyl-7-oxo-2,3,3a,3b,4,5,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-cyclopenta[i]phenanthridine-1-carboxamide
-
(1S,9aR,11aS)-N-[2-tert-butyl-5-(trifluoromethyl)phenyl]-9a,11a-dimethyl-7-oxo-2,3,3a,3b,4,5,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-cyclopenta[i]phenanthridine-1-carboxamide
-
(1S,9aR,11aS)-N-[bis(4-chlorophenyl)methyl]-9a,11a-dimethyl-7-oxo-2,3,3a,3b,4,5,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-cyclopenta[i]phenanthridine-1-carboxamide
-
(1S,9aS,11aS)-N,N-diethyl-8,9a,11a-trimethyl-7-oxo-2,3,3a,3b,4,5,7,9a,9b,10,11,11a-dodecahydro-1H-cyclopenta[i]phenanthridine-1-carboxamide
-
(20E)-20-(hydroxyimino)pregn-4-en-3-one
-
(20E)-20-(hydroxyimino)pregn-4-ene-3,6-dione
-
(20E)-20-(hydroxyimino)pregna-4,14,16-trien-3-one
-
(20E)-20-(hydroxyimino)pregna-4,16-dien-3-one
-
(21E)-21-(hydroxyimino)pregn-4-en-3-one
-
(22R,S)-N-(1,1,1-trifluoro-2-phenylprop-2-yl)-3-oxo-4-aza-5-androst-1-ene-17-carboxamide
i.e. FCE 28260; i.e. FCE 28260
(2R,3R,10aR,12aS)-2,10a,12a-trimethyl-1,8-dioxo-3-phenyl-1,2,3,4,4a,4b,8,10a,10b,11,12,12a-dodecahydrochrysen-2-yl acetate
-
(2R,3R,10aR,12aS)-2,10a,12a-trimethyl-1,8-dioxo-3-phenyl-1,2,3,4,4a,4b,8,9,10,10a,10b,11,12,12a-tetradecahydrochrysen-2-yl (2-fluorophenyl)acetate
(2R,3R,10aR,12aS)-2,10a,12a-trimethyl-1,8-dioxo-3-phenyl-1,2,3,4,4a,4b,8,9,10,10a,10b,11,12,12a-tetradecahydrochrysen-2-yl (3-fluorophenyl)acetate
-
-
(2R,3R,10aR,12aS)-2,10a,12a-trimethyl-1,8-dioxo-3-phenyl-1,2,3,4,4a,4b,8,9,10,10a,10b,11,12,12a-tetradecahydrochrysen-2-yl acetate
-
(2R,3R,10aR,12aS)-2,10a,12a-trimethyl-1,8-dioxo-3-phenyl-1,2,3,4,4a,4b,8,9,10,10a,10b,11,12,12a-tetradecahydrochrysen-2-yl phenylacetate
-
-
(2R,3R,10aR,12aS)-2-hydroxy-2,10a,12a-trimethyl-3-phenyl-3,4,4a,10a,10b,11,12,12a-octahydrochrysene-1,8(2H,4bH)-dione
-
(2R,3R,10aR,12aS)-2-hydroxy-2,10a,12a-trimethyl-3-phenyl-3,4,4a,9,10,10a,10b,11,12,12a-decahydrochrysene-1,8(2H,4bH)-dione
-
(2S,9aR,11aR)-2-(4-chlorophenoxy)-5,9a,11a-trimethyl-1,2,3,3a,3b,4,5,8,9,9a,9b,10,11,11a-tetradecahydro-7H-cyclopenta[i]phenanthridin-7-one
-
(3beta)-6,20-dioxopregna-4,16-dien-3-yl 3-bromopropanoate
-
(3beta)-6,20-dioxopregna-4,16-dien-3-yl 3-chloropropanoate
-
(3beta)-6,20-dioxopregna-4,16-dien-3-yl 3-iodopropanoate
-
(3beta)-6,20-dioxopregna-4,16-dien-3-yl propanoate
-
(3E,4aR,6aS,7S,11aR)-N,N-diethyl-3-(hydroxymethylidene)-1,4a,6a-trimethyl-2-oxohexadecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
-
(4-[4-(4-bromophenoxy)benzoyl]phenyl)acetic acid
-
pH 5.5, 55% inhibition at 0.01 mM, pH 6.6, 59% inhibition at 0.01 mM
(4-[[1-(dicyclohexylacetyl)piperidin-4-ylidene]methyl]-3-fluorophenyl)acetic acid
-
(4-[[1-(dicyclohexylacetyl)piperidin-4-ylidene]methyl]phenyl)acetic acid
-
(4alpha,5alpha)-3,20-dioxo-4,5-epoxypregnan-17-yl 4-bromobenzoate
-
-
(4alpha,5alpha)-3,20-dioxo-4,5-epoxypregnan-17-yl benzoate
-
-
(4aR,10bR)-4,10b-dimethyl-8-[(E)-2-phenylethenyl]-1,4,4a,5,6,10b-hexahydrobenzo[f]quinolin-3(2H)-one
-
(4aR,10bR)-4,8-dimethyl-1,4,4a,5,6,10b-hexahydrobenzo[f]quinolin-3(2H)-one
-
(4aR,10bR)-8-(furan-2-yl)-4,10b-dimethyl-1,4,4a,5,6,10b-hexahydrobenzo[f]quinolin-3(2H)-one
-
(4aR,10bR)-8-bromo-4-methyl-1,4,4a,5,6,10b-hexahydrobenzo[f]quinolin-3(2H)-one
-
(4aR,10bR)-8-chloro-1,4,4a,5,6,10b-hexahydrobenzo[f]quinolin-3(2H)-one
-
(4aR,10bR)-8-chloro-4,10b-dimethyl-1,4,4a,5,6,10b-hexahydrobenzo[f]quinolin-3(2H)-one
-
(4aR,10bR)-8-chloro-4,10b-dimethyl-1,4,4a,5,6,10b-hexahydrobenzo[f]quinoline-3(2H)-thione
21.6% inhibition at 0.04 mM
(4aR,10bR)-8-chloro-4-methyl-1,4,4a,5,6,10b-hexahydrobenzo[f]quinolin-3(2H)-one
i.e. LY191704; i.e. LY191704
(4aR,10bR)-8-fluoro-4-methyl-1,4,4a,5,6,10b-hexahydrobenzo[f]quinolin-3(2H)-one
-
(4aR,10bR)-8-[(E)-2-(isoquinolin-4-yl)ethenyl]-4,10b-dimethyl-1,4,4a,5,6,10b-hexahydrobenzo[f]quinolin-3(2H)-one
-
(4aR,5S,6aS,11aR)-N-(diphenylmethyl)-5-hydroxy-1,4a,6a,10-tetramethyl-2-oxo-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
(4aR,5S,6aS,11aR)-N-(diphenylmethyl)-5-hydroxy-4a,6a,10-trimethyl-2-oxo-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
(4aR,6aR)-1,4a,6a,10-tetramethyl-7-(6-methylheptan-2-yl)-1,3,4,4a,4b,5,6,6a,7,8,9,9a,9b,10-tetradecahydro-2H-indeno[5,4-f]quinolin-2-one
-
(4aR,6aR)-1,4a,6a,10-tetramethyl-7-(6-methylheptan-2-yl)-1,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-2H-indeno[5,4-f]quinolin-2-one
-
(4aR,6aR)-1,4a,6a-trimethyl-7-(6-methylheptan-2-yl)-10-propyl-1,3,4,4a,4b,5,6,6a,7,8,9,9a,9b,11a-tetradecahydro-2H-indeno[5,4-f]quinolin-2-one
-
(4aR,6aR)-1,4a,6a-trimethyl-7-(6-methylheptan-2-yl)hexadecahydro-2H-indeno[5,4-f]quinolin-2-one
-
(4aR,6aR)-10-ethyl-1,4a,6a-trimethyl-7-(6-methylheptan-2-yl)hexadecahydro-2H-indeno[5,4-f]quinolin-2-one
-
(4aR,6aR)-4a,6a,10-trimethyl-7-(6-methylheptan-2-yl)-1,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-2H-indeno[5,4-f]quinolin-2-one
-
(4aR,6aS,11aR)-1,4a,6a,10-tetramethyl-2-oxo-N-(4,4,4-trifluoro-2-methyl-3-oxobutan-2-yl)-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
-
(4aR,6aS,11aR)-1,4a,6a,10-tetramethyl-2-oxo-N-(4,4,4-trifluoro-3-oxobutan-2-yl)-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
-
(4aR,6aS,11aR)-1,4a,6a,10-tetramethyl-N-(2-methyl-4-oxopentan-3-yl)-2-oxo-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
-
(4aR,6aS,11aR)-N-(2-cyanopropan-2-yl)-1,4a,6a,10-tetramethyl-2-oxo-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
(4aR,6aS,7E,11aR)-7-(chloromethylidene)-1,6a-dimethylhexadecahydro-2H-indeno[5,4-f]quinolin-2-one
i.e. azaestranone II; i.e. azaestranone II
(4aR,6aS,7S)-1,4a,6a-trimethyl-2,5-dioxo-N-phenyl-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
-
(4aR,6aS,7S)-1,4a,6a-trimethyl-2,5-dioxo-N-phenylhexadecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
-
(4aR,6aS,7S)-1,4a,6a-trimethyl-2,5-dioxo-N-[2-(trifluoromethyl)phenyl]-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
-
(4aR,6aS,7S)-4a,6a-dimethyl-2,5-dioxo-N-phenyl-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
-
(4aR,6aS,7S)-4a,6a-dimethyl-2,5-dioxo-N-phenylhexadecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
-
(4aR,6aS,7S)-N,1,4a,6a-tetramethyl-2,5-dioxo-N-phenyl-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
-
(4aR,6aS,7S)-N,4a,6a-trimethyl-2,5-dioxo-N-phenyl-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
-
(4aR,6aS,7S)-N-(2-chlorophenyl)-1,4a,6a-trimethyl-2,5-dioxo-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
-
(4aR,6aS,7S)-N-[2,5-bis(trifluoromethyl)phenyl]-1,4a,6a-trimethyl-2,5-dioxo-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
-
(4aR,6aS,7S,11aR)-1,4a,6a-trimethyl-N-(3-methylbutanoyl)-2-oxo-N-(propan-2-yl)-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
(4aR,6aS,7S,11aR)-1,4a,6a-trimethyl-N-(3-methylbutanoyl)-2-oxo-N-(propan-2-yl)hexadecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
(4aR,6aS,7S,11aR)-4a,6a-dimethyl-2-oxo-N-(4,4,4-trifluoro-3-oxobutan-2-yl)-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
-
(4aR,6aS,7S,11aR)-4a,6a-dimethyl-4,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-indeno[5,4-f]isoquinolin-7-ol 2-oxide
-
(4aR,6aS,7S,11aR)-4a,6a-dimethyl-N-(3-methylbutanoyl)-2-oxo-N-(propan-2-yl)-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
(4aR,6aS,7S,11aR)-4a,6a-dimethyl-N-(3-methylbutanoyl)-2-oxo-N-(propan-2-yl)hexadecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
(4aR,6aS,7S,11aR)-7-hydroxy-1,4a,6a-trimethylhexadecahydro-2H-indeno[5,4-f]quinolin-2-one
-
(4aR,6aS,7S,11aR)-N-(3,3-dimethylpentanoyl)-1,4a,6a-trimethyl-N-(2-methylbutan-2-yl)-2-oxohexadecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
(4aR,6aS,7S,11aR)-N-(diphenylmethyl)-1,4a,6a-trimethyl-2,5-dioxohexadecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
(4aR,6aS,7S,11aR)-N-(diphenylmethyl)-4a,6a-dimethyl-2,5-dioxo-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
(4aR,6aS,7S,11aR)-N-(diphenylmethyl)-4a,6a-dimethyl-2,5-dioxohexadecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
(4aR,6aS,7S,11aR)-N-cyclohexyl-N-(cyclohexylacetyl)-1,4a,6a-trimethyl-2-oxohexadecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
(4aR,6aS,7S,11aR)-N-[2,5-bis(trifluoromethyl)phenyl]-4a,6a-dimethyl-2-oxo-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
-
(4aR,7S)-8-ethyl-4a,7-dimethyl-10-methylidene-7-[(2S)-3-oxobutan-2-yl]-4,4a,4b,5,6,7,8,8a,9,10-decahydrophenanthren-2(3H)-one
-
(4aS,6aS,7S,11aR)-4a,6a-dimethyl-2,3,4,4a,5,6,6a,7,8,9,9a,10,11,11a-tetradecahydro-1H-indeno[5,4-f]isoquinolin-7-ol
-
(4aS,6aS,7S,11aS)-4a,6a-dimethyl-2-oxo-N,N-diphenyl-2,3,4,4a,5,6,6a,7,8,9,9a,10,11,11a-tetradecahydro-1H-indeno[4,5-h]isoquinoline-7-carboxamide
-
(4aS,6aS,7S,11aS)-4a,6a-dimethyl-2-oxo-N-phenyl-2,3,4,4a,5,6,6a,7,8,9,9a,10,11,11a-tetradecahydro-1H-indeno[4,5-h]isoquinoline-7-carboxamide
-
(4aS,6aS,7S,11aS)-4a,6a-dimethyl-2-oxo-N-[2-(trifluoromethyl)phenyl]-2,3,4,4a,5,6,6a,7,8,9,9a,10,11,11a-tetradecahydro-1H-indeno[4,5-h]isoquinoline-7-carboxamide
-
(4aS,6aS,7S,11aS)-4a,6a-dimethyl-4,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-indeno[4,5-h]isoquinolin-7-ol 3-oxide
-
(4aS,6aS,7S,11aS)-4a,6a-dimethyl-7-[methyl(phenyl)carbamoyl]-2-oxo-2,3,4,4a,5,6,6a,7,8,9,9a,10,11,11a-tetradecahydro-1H-indeno[4,5-h]isoquinolinium
-
(4aS,6aS,7S,11aS)-N,N-di(1H-indol-1-yl)-4a,6a-dimethyl-2-oxo-2,3,4,4a,5,6,6a,7,8,9,9a,10,11,11a-tetradecahydro-1H-indeno[4,5-h]isoquinoline-7-carboxamide
-
(4aS,6aS,7S,11aS)-N-(biphenyl-3-yl)-4a,6a-dimethyl-2-oxo-2,3,4,4a,5,6,6a,7,8,9,9a,10,11,11a-tetradecahydro-1H-indeno[4,5-h]isoquinoline-7-carboxamide
-
(4R)-5,10-seco-19-nor-pregna-4,5-diene-3,10,20-trione
a non-competitive and possibly irreversible inhibitor; a non-competitive and possibly irreversible inhibitor
(4R)-5,10-seco-estra-4,5-diene-3,10,17-trione
a non-competitive and possibly irreversible inhibitor; a non-competitive and possibly irreversible inhibitor
(5,20R)-4-diazo-21-hydroxy-20-methyl-pregn-6-en-3-one
i.e. RMI-18,341; i.e. RMI-18,341
(5alpha,6alpha)-20-oxo-5,6-epoxypregn-16-en-3-yl acetate
(5alpha17beta)-17-N,N-diethylcarbamoyl-4-methyl-4-aza-5-androstan-3-one
-
(5aR,7aS,8S,12aR)-5a,7a-dimethyl-2-oxooctadecahydrocyclopenta[5,6]naphtho[2,1-b]azepin-8-yl acetate
-
(5aR,9aR,11aS)-1-(3,3-dimethylbutanoyl)-6,9a,11a-trimethyl-1,2,3,3a,3b,4,5,5a,6,9a,9b,10,11,11a-tetradecahydro-7H-indolo[5,4-f]quinolin-7-one
-
(5aR,9aR,11aS)-1-(3,3-dimethylbutanoyl)-6,9a,11a-trimethylhexadecahydro-7H-indolo[5,4-f]quinolin-7-one
-
(5aR,9aR,11aS)-1-(3,3-dimethylbutanoyl)-9a,11a-dimethyl-1,2,3,3a,3b,4,5,5a,6,9a,9b,10,11,11a-tetradecahydro-7H-indolo[5,4-f]quinolin-7-one
-
(5aR,9aR,11aS)-1-(3,3-dimethylbutanoyl)-9a,11a-dimethylhexadecahydro-7H-indolo[5,4-f]quinolin-7-one
-
(6aR,7S,9aR,11aS)-7-hydroxy-1,9a,11a-trimethylhexadecahydro-2H-indeno[5,4-f]quinolin-2-one
-
(6aS,10aS,12aS)-1,10a,12a-trimethylhexadecahydronaphtho[2,1-f]quinoline-2,8-dione
-
(6aS,7S)-6a-methyl-N-(propan-2-yl)-5,6,6a,7,8,9,9a,9b-octahydro-4bH-indeno[5,4-f]isoquinoline-7-carboxamide 2-oxide
-
(6aS,7S)-N,N-diethyl-6a-methyl-5,6,6a,7,8,9,9a,9b-octahydro-4bH-indeno[5,4-f]isoquinoline-7-carboxamide 2-oxide
-
(6aS,8S,10aS,12aS)-8-hydroxy-1,10a,12a-trimethylhexadecahydronaphtho[2,1-f]quinolin-2(1H)-one
-
(6beta)-6-bromo-16-methyl-17-[(1-phenylethenyl)oxy]pregna-4,6-diene-3,20-dione
-
(7-chloro-3,4,4a,9-tetrahydrophenanthren-2-yl)phosphinic acid
-
(7aR,9aS,10S)-N,N-diethyl-7a,9a-dimethyl-5-oxo-1,2,3,5,6,7,7a,7b,8,9,9a,10,11,12,12a,12b-hexadecahydrobenzo[b]indeno[5,4-d]azepine-10-carboxamide
-
(7aS,8S,10aS,10bS)-N-tert-butyl-7a-methyl-2-oxo-2,3,4,5a,6,7,7a,8,9,10,10a,10b,11,12-tetradecahydrocyclopenta[f]pyrido[1,2-a]quinoline-8-carboxamide
-
(7aS,8S,12aR)-7a-methyl-8-(phenylamino)-5a,6,7,7a,8,9,10,10a,10b,11,12,12a-dodecahydrocyclopenta[f]pyrido[1,2-a]quinolin-2(1H)-one
-
(7aS,8S,12aR)-8-[benzyl(phenyl)amino]-7a-methyl-5a,6,7,7a,8,9,10,10a,10b,11,12,12a-dodecahydrocyclopenta[f]pyrido[1,2-a]quinolin-2(1H)-one
-
(8a,9b,10x,14x)-N-tert-butyl-3-oxoestr-4-ene-17-carboxamide
-
(8R,9aS,11aS)-1,9a,11a-trimethyl-2-oxo-N,N-di(propan-2-yl)hexadecahydro-1H-indeno[5,4-f]quinoline-8-carboxamide
-
(9aR,11aS)-1-(3,3-dimethylbutanoyl)-6,9a,11a-trimethyl-1,2,3,3a,3b,4,6,8,9,9a,9b,10,11,11a-tetradecahydro-7H-indolo[5,4-f]quinolin-7-one
-
(S)-4-[1-[4-[[1-(4-isobutylphenyl)butyl]oxy]benzoyl]indolizin-3-yl]-butyric acid
(S)-4-[1-[4-[[1-(4-isobutylphenyl)butyl]oxy]benzoyl]indolizin-3-yl]butyric acid
1,10-phenanthroline
-
1 mM, 29% inhibition
1,4,5,6-tetrahydrobenzo[f]quinolin-3(2H)-one
-
1,4,6-pregnatriene-3,20-dione
-
-
1,4-androstadiene-3,17-dione
-
-
1-(3-carboxypropyl)-4-[4-([[3-(2-methylpropyl)phenyl][4-(2-methylpropyl)phenyl]methyl]amino)benzoyl]-1H-pyrrole-3-carboxylic acid
1-cyclopropyl-3-ethyl-1-[(4aR,6aS,7S,11aR)-1,4a,6a-trimethyl-2-oxohexadecahydro-1H-indeno[5,4-f]quinolin-7-yl]urea
20% inhibition at 100 nM in transfected SW-13 cells
1-cyclopropyl-3-methyl-1-[(4aR,6aS,7S,11aR)-1,4a,6a,10-tetramethyl-2-oxohexadecahydro-1H-indeno[5,4-f]quinolin-7-yl]urea
-
1-cyclopropyl-3-phenyl-1-[(4aR,6aS,7S,11aR)-1,4a,6a,10-tetramethyl-2-oxohexadecahydro-1H-indeno[5,4-f]quinolin-7-yl]urea
-
1-cyclopropyl-3-phenyl-1-[(4aR,6aS,7S,11aR)-1,4a,6a-trimethyl-2-oxohexadecahydro-1H-indeno[5,4-f]quinolin-7-yl]urea
39.7% inhibition at 100 nM in transfected SW-13 cells; 56.3% inhibition at 100 nM in transfected SW-13 cells
1-methyl-5-phenylpiperidin-2-one
13.5% inhibition at 0.04 mM
1-methyl-5-[4-(phenylacetyl)phenyl]pyridin-2(1H)-one
61% inhibition at 0.010 mM
1-methyl-5-[4-[(E)-2-phenylethenyl]phenyl]piperidin-2-one
-
1-methyl-5-[4-[(E)-phenyldiazenyl]phenyl]piperidin-2-one
-
16,16-dimethylandrost-4-ene-3,17-dione
16-ethyl-17beta-hydroxy-4-estren-3-one
17-(2-cyclopentylethoxy)-6-methylidenepregn-4-ene-3,20-dione
-
17-(3-cyclopentylpropoxy)-6-methylidenepregn-4-ene-3,20-dione
-
17-hydroxy-6-methylidenepregn-4-ene-3,20-dione
-
17-hydroxyestra-4,8-dien-3-one
-
17-hydroxyestra-4,9(11)-dien-3-one
-
17-hydroxypregna-4,6-diene-3,20-dione
-
-
17beta-(N-tert-butyl carbamoyl)-19-nor-10-aza-4-androsten-3-one
-
17beta-(N-tert-butylcarbamoyl)-4-aza-5alpha-androst-1-en-3-one
-
17beta-N,N-diethylcarbamoyl-4-methyl-4-aza-5alpha-androstan-3-one
17beta-N-(2,5-bis(trifluoromethyl)-phenyl)-3-oxo-4-aza-5alpha-androst-1-ene-17-carboxamide
-
1alpha,2alpha-epoxy-4,6-pregnadiene-3,20-dione
-
-
2',3'-tetrahydrofuran-2'-spiro-17-(6-methylene-4-androsten-3-one)
2,2'-dipyridyl
-
1 mM, 22% inhibition
2-(trifluoromethyl)phenyl 4-methyl-3-oxo-2,3,5,6-tetrahydro-1H-pyrido[1,2-a]quinoline-8-carboxylate
368% inhibition at 0.01 mM; 42% inhibition at 0.010 mM
2-fluorophenyl 4-methyl-3-oxo-2,3,5,6-tetrahydro-1H-pyrido[1,2-a]quinoline-8-carboxylate
138% inhibition at 0.010 mM; 166% inhibition at 0.01 mM
2-methyl-N-phenyl-N-[(4aR,6aS,7S,11aR)-1,4a,6a-trimethyl-2-oxohexadecahydro-1H-indeno[5,4-f]quinolin-7-yl]propanamide
-
2-oxo-8-(prop-2-en-1-yl)-2H-chromen-7-yl benzoate
-
2-[4-(1,2-dimethyl-6-oxo-1,2,3,6-tetrahydropyridin-3-yl)phenoxy]-N-(propan-2-yl)acetamide
3% inhibition at 0.010 mM
2-[4-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenoxy]-N-(prop-2-en-1-yl)acetamide
6% inhibition at 0.010 mM
2-[4-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenoxy]-N-(propan-2-yl)acetamide
8% inhibition at 0.010 mM
2-[4-(1-methyl-6-oxopiperidin-3-yl)phenoxy]-N-(propan-2-yl)acetamide
6% inhibition at 0.010 mM
2-[[16-(acetylsulfanyl)hexadecanoyl]amino]ethyl (4Z)-6-([[4-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenoxy]acetyl]amino)hex-4-enoate
43% inhibition at 0.010 mM
20-hydroxyimino-1,4-pregnadiene-3-one
-
-
20-hydroxyimino-4-pregnene-3-one
-
-
20-hydroxyimino-5-oxo-A-nor-3,5-secopregnan-3-oic acid
-
-
20-oxo-16,17-epoxypregn-5-en-3-yl acetate
-
3,20-dioxopregn-4-en-17-yl (4-bromophenyl)carbamate
-
3,20-dioxopregn-4-en-17-yl phenylcarbamate
-
3,20-dioxopregna-4,6-dien-17-yl (4-bromophenyl)carbamate
-
-
3,20-dioxopregna-4,6-dien-17-yl 4-bromobenzoate
3,20-dioxopregna-4,6-dien-17-yl 4-chlorobenzoate
-
-
3,20-dioxopregna-4,6-dien-17-yl 4-fluorobenzoate
3,20-dioxopregna-4,6-dien-17-yl benzoate
3,20-dioxopregna-4,6-dien-17-yl phenylcarbamate
-
-
3-(2,4-dimethoxyphenyl)-5-methoxy-8,8-dimethyl-4H,8H-pyrano[2,3-f]chromen-4-one
3-(2-[[16-(acetylsulfanyl)hexadecanoyl]amino]ethoxy)propyl (4Z)-6-([[4-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenoxy]acetyl]amino)hex-4-enoate
33% inhibition at 0.010 mM
3-butyl-1-cyclopropyl-1-[(4aR,6aS,7S,11aR)-1,4a,6a-trimethyl-2-oxo-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-indeno[5,4-f]quinolin-7-yl]urea
4.9% inhibition at 100 nM in transfected SW-13 cells
3-butyl-1-cyclopropyl-1-[(4aR,6aS,7S,11aR)-1,4a,6a-trimethyl-2-oxohexadecahydro-1H-indeno[5,4-f]quinolin-7-yl]urea
46.3% inhibition at 100 nM in transfected SW-13 cells
3-chloro-4-(4-[N-(4-phenoxybenzyl)amino] phenoxy)benzoic acid
-
-
3-chloro-4-(4-[N-(4-phenoxybenzyl)amino]phenoxy)benzoic acid
-
3-chloro-4-([1-(4-methoxybenzyl)-2,3-dihydro-1H-indol-5-yl]oxy)benzoic acid
-
3-chloro-4-([1-(4-phenoxybenzoyl)-1H-indol-5-yl]oxy)benzoic acid
-
3-chloro-4-([1-(4-phenoxybenzyl)indolin-5-yl]oxy)benzoic acid
3-chloro-4-([1-(furan-2-ylmethyl)-2,3-dihydro-1H-indol-5-yl]oxy)benzoic acid
-
3-chloro-4-[(1-(4-phenoxybenzoyl)-1H-indol-5-yl]oxy)benzoic acid
-
-
3-chloro-4-[[1-(4-methoxybenzyl)-2,3-dihydro-1H-indol-5-yl]oxy]benzoic acid
-
3-cyclohexyl-1-cyclopropyl-1-[(4aR,6aS,7S,11aR)-1,4a,6a,10-tetramethyl-2-oxohexadecahydro-1H-indeno[5,4-f]quinolin-7-yl]urea
-
3-cyclohexyl-1-cyclopropyl-1-[(4aR,6aS,7S,11aR)-1,4a,6a-trimethyl-2-oxohexadecahydro-1H-indeno[5,4-f]quinolin-7-yl]urea
48.7% inhibition at 100 nM in transfected SW-13 cells
3-fluorophenyl 4-methyl-3-oxo-2,3,5,6-tetrahydro-1H-pyrido[1,2-a]quinoline-8-carboxylate
134% inhibition at 0.01 mM; 160% inhibition at 0.010 mM
3-hydroxy-16,17-epoxypregn-5-en-20-one
-
3-[2,4-bis(benzyloxy)phenyl]-5-methoxy-8,8-dimethyl-4H,8H-pyrano[2,3-f]chromen-4-one
3-[2,4-bis(benzyloxy)phenyl]-5-methoxy-8,8-dimethyl-8,9-dihydro-4H,10H-pyrano[2,3-f]chromene-4,10-dione
3-[4-(4-phenoxybenzoyl)phenyl]acrylic acid
3beta-acetoxy-20-hydroxyimino-5-pregnene
-
-
3beta-acetoxy-5-pregnen-20-one
-
-
3beta-hydroxy-20-hydroxyiminopregnenolone
-
-
4'-(tricyclo[3.3.1.13,7]dec-2-ylcarbamoyl)biphenyl-4-carboxylic acid
4'-[2-[di(propan-2-yl)amino]-2-oxoethoxy]-3',5'-di(propan-2-yl)biphenyl-4-carboxylic acid
-
4'-[2-[di(propan-2-yl)amino]-2-oxoethoxy]-3'-fluoro-5'-nitrobiphenyl-4-carboxylic acid
-
4,4a,5,6,7,8,9,10-octahydro-3H-pyrido[1,2-a]quinolin-3-one
-
4,8-dimethyl-1,2,5,6-tetrahydro-3H-pyrido[1,2-a]quinolin-3-one
-
4-(1-benzyl-1H-indol-5-yl)benzoic acid
-
4-(2-[1-(4,4'-dipropylbenzhydryl)indole-5-carboxamido]phenoxy)butyric acid
4-(2-[[(2E)-3-[1-[bis(4-fluorophenyl)methyl]-1H-indol-5-yl]pent-2-enoyl]amino]phenoxy)butanoic acid
i.e. KF20405; i.e. KF20405
4-(3-(4-(N-methylacetamido)phenyl) pentan-3-yl) phenyldibenzylcarbamate
-
4-(3-[[2,2-bis(4-chlorophenyl)-1,3-benzodioxol-5-yl]carbonyl]-2-methyl-1H-indol-1-yl)butanoic acid
-
4-(4-([2,6-bis(trifluoromethyl)benzyl]oxy)benzoyl)benzoic acid
-
pH 5.5, 29% inhibition at 0.01 mM, pH 6.6, 69% inhibition at 0.01 mM
4-(4-benzoylphenoxy)benzoic acid
-
4-(4-phenoxybenzoyl)benzoic acid
4-(4-[[2,6-bis(trifluoromethyl)benzyl]oxy]benzoyl)benzoic acid
-
pH 5.5, isoform 2, 50% inhibition at 0.000113 mM, isoform 1, 12% inhibition at 0.01 mM
4-(biphenyl-4-yloxy)-2-chlorobenzoic acid
-
4-(biphenyl-4-yloxy)-2-fluorobenzoic acid
-
4-(biphenyl-4-yloxy)-3-methoxybenzoic acid
-
4-(methoxycarbonyl)phenyl 4-methyl-3-oxo-2,3,5,6-tetrahydro-1H-pyrido[1,2-a]quinoline-8-carboxylate
129% inhibition at 0.010 mM; 584% inhibition at 0.01 mM
4-androsten-3-one-17-carboxylic acid
competitive
4-aza-20-hydroxyimino-5-pregnene-3-one
-
an 4-azasteroid
4-bromo-3,20-dioxopregn-4-en-17-yl 4-chlorobenzoate
-
4-bromo-3,20-dioxopregn-4-en-17-yl 4-fluorobenzoate
-
4-bromo-3,20-dioxopregna-1,4-dien-17-yl acetate
-
4-fluorophenyl 4-methyl-3-oxo-2,3,5,6-tetrahydro-1H-pyrido[1,2-a]quinoline-8-carboxylate
119% inhibition at 0.01 mM; 93% inhibition at 0.010 mM
4-methylphenyl 4-methyl-3-oxo-2,3,5,6-tetrahydro-1H-pyrido[1,2-a]quinoline-8-carboxylate
102% inhibition at 0.010 mM; 553% inhibition at 0.01 mM
4-trifluoromethyl-N-(tert-butyl)-4-androsten-17beta-carboxamide
-
4-[(1-benzyl-1H-indol-5-yl)oxy]-3-chlorobenzoic acid
4-[1-(6,6-dimethyl-6H-dibenzo[b,d]pyran-3-yl)methylindol-3-yl]-butyric acid
4-[2-(1-methyl-6-oxopiperidin-3-yl)ethyl]-N,N-di(propan-2-yl)benzamide
4-[2-(5-[[bis(4-fluorophenyl)methyl]carbamoyl]-1-benzofuran-2-yl)phenoxy]butanoic acid
-
4-[2-(6-[[bis(4-fluorophenyl)methyl]carbamoyl]-1-benzofuran-2-yl)phenoxy]butanoic acid
4-[3-(1-methyl-6-oxopiperidin-3-yl)butan-2-yl]-N,N-di(propan-2-yl)benzamide
4-[3-(4-[(1R)-1-[4-(2-methylpropyl)phenyl]ethoxy]benzoyl)-1H-indol-1-yl]butanoic acid
-
4-[3-(benzyloxy)benzoyl]benzoic acid
4-[3-([(2R)-2-methyl-2-[4-(2-methylpropyl)phenyl]-1,3-benzodioxol-5-yl]carbonyl)-1H-indol-1-yl]butanoic acid
-
4-[3-ethyl-4-[4-([[3-(2-methylpropyl)phenyl][4-(2-methylpropyl)phenyl]methyl]amino)benzoyl]-1H-pyrrol-1-yl]butanoic acid
4-[3-[3-([[3-(2-methylpropyl)phenyl][4-(2-methylpropyl)phenyl]methyl]amino)benzoyl]-4-(propan-2-yl)-1H-pyrrol-1-yl]butanoic acid
4-[3-[3-[bis (4-isobutylphenyl)methyl amino] benzoyl]-lH-indol-l-yl] butyric acid
i.e. FK-143
4-[3-[3-[bis (4-isobutylphenyl)methylamino]benzoyl]-lH-indol-l-yl] butyric acid
4-[3-[3-[bis(4-isobutylphenyl)methylamino]benzoyl]-lH-indol-l-yl]butyric acid
4-[3-[4-([[3-(2-methylpropyl)phenyl][4-(2-methylpropyl)phenyl]methyl]amino)benzoyl]-1H-pyrrol-1-yl]butanoic acid
4-[3-[4-([[3-(2-methylpropyl)phenyl][4-(2-methylpropyl)phenyl]methyl]amino)benzoyl]-4-(propan-2-yl)-1H-pyrrol-1-yl]butanoic acid
4-[4-(4-methylbenzoyl)phenoxy]benzoic acid
-
4-[4-(benzyloxy)benzoyl]benzoic acid
4-[4-(tricyclo[3.3.1.13,7]dec-2-ylcarbamoyl)phenoxy]benzoic acid
4-[4-[di(propan-2-yl)carbamoyl]-2-ethylphenyl]cyclohex-1-ene-1-carboxylic acid
-
4-[[1-(2-propylpentanoyl)piperidin-4-ylidene]methyl]benzoic acid
4-[[1-(biphenyl-4-ylcarbamoyl)piperidin-4-ylidene]methyl]benzoic acid
4-[[1-(dicyclohexylacetyl)piperidin-4-ylidene]methyl]-3-fluorobenzoic acid
-
4-[[1-(dicyclohexylacetyl)piperidin-4-ylidene]methyl]benzoic acid
4-[[1-(diphenylacetyl)piperidin-4-ylidene]methyl]benzoic acid
5-(2-ethyl-3-[3-[(4-hexylundecyl)amino]benzoyl]-1H-pyrrol-1-yl)pentanoate
5-(4-chlorophenyl)-1-methylpiperidin-2-one
-
5-(4-chlorophenyl)-1-methylpiperidine-2-thione
14% inhibition at 0.04 mM
5-(benzyloxy)-1H-indole-2-carboxylic acid
-
5-bromo-N-pentyl-N-[(4aR,6aS,7S,11aR)-1,4a,6a-trimethyl-2-oxohexadecahydro-1H-indeno[5,4-f]quinolin-7-yl]pentanamide
-
5alpha,6alpha-epoxy-3beta-acetoxy-20-hydroxyiminopregnane
-
-
5alpha,6alpha-epoxy-3beta-acetoxypregnan-20-one
-
-
5alpha,6alpha-epoxy-3beta-hydroxypregnan-20-one
-
-
5beta,6beta-epoxy-3beta-acetoxy-20-hydroxyiminopregnane
-
-
5beta,6beta-epoxy-3beta-acetoxypregnan-20-one
-
-
6,20-dioxopregn-4-en-3-yl 4-bromobenzoate
-
6,20-dioxopregn-4-en-3-yl 4-fluorobenzoate
-
6,20-dioxopregn-4-en-3-yl 5-chloropentanoate
-
6,20-dioxopregna-4,16-dien-3-yl 3-bromopropanoate
-
-
6,20-dioxopregna-4,16-dien-3-yl 3-chloropropanoate
-
-
6,20-dioxopregna-4,16-dien-3-yl 3-iodopropanoate
-
-
6,20-dioxopregna-4,16-dien-3-yl 4-bromobenzoate
-
6,20-dioxopregna-4,16-dien-3-yl 4-fluorobenzoate
-
6,20-dioxopregna-4,16-dien-3-yl 4-methylbenzoate
-
6,20-dioxopregna-4,16-dien-3-yl acetate
6,20-dioxopregna-4,16-dien-3-yl benzoate
6,8-dimethyl-1,2,5,6-tetrahydro-3H-pyrido[1,2-a]quinolin-3-one
-
6-(benzyloxy)-5-methoxy-1-methyl-1H-indole-2-carboxylic acid
-
6-([5-[(1R,4aR,6aR,7R,11aR)-1,4a,6a-trimethyl-1-oxidohexadecahydro-1H-indeno[5,4-f]quinolin-7-yl]hexanoyl]amino)hexanoic acid
-
6-([5-[(1S,4aR,6aR,7R,11aR)-1,4a,6a-trimethyl-1-oxidohexadecahydro-1H-indeno[5,4-f]quinolin-7-yl]hexanoyl]amino)hexanoic acid
-
6-bromo-3,20-dioxopregna-4,6-dien-17-yl acetate
6-chloro-3,20-dioxopregna-4,6-dien-17-yl 4-bromobenzoate
6-chloro-3,20-dioxopregna-4,6-dien-17-yl 4-chlorobenzoate
-
-
6-chloro-3,20-dioxopregna-4,6-dien-17-yl 4-fluorobenzoate
6-chloro-3,20-dioxopregna-4,6-dien-17-yl benzoate
6-hydroxy-9,10-dimethoxy-3,3-dimethyl-3H-chromeno[3,4-b]pyrano[2,3-h]chromen-7(13H)-one
6-methylidene-3,20-dioxopregn-4-en-17-yl 4-bromobenzoate
-
6-[(1R,4aR,6aR,7R,11aR)-7-[6-[(4-cyanobenzyl)oxy]hexan-2-yl]-4a,6a-dimethyl-1-oxidohexadecahydro-1H-indeno[5,4-f]quinolin-1-yl]hexanoic acid
-
6-[(1S,4aR,6aR,7R,11aR)-7-[6-[(4-cyanobenzyl)oxy]hexan-2-yl]-4a,6a-dimethyl-1-oxidohexadecahydro-1H-indeno[5,4-f]quinolin-1-yl]hexanoic acid
-
6-[3-(N,N-dicyclohexylaminocarbonyl) phenyl]-3,4-dihydro-naphthalene-2-carboxylate
-
6-[3-(N,N-dicyclohexylaminocarbonyl)phenyl]-3,4-dihydro-naphthalene-2-carboxylic acid
-
6-[4-(N,N-diisopropylamino-carbonyl) phenyl]naphthalene-2-carboxylic acid
-
6-[4-(N,N-diisopropylamino-carbonyl)phenyl]naphthalene-2-carboxylic acid
uncompetitive
6-[4-(N,N-diisopropylcarbamoyl) phenyl]-1H-quinolin-2-one
competitive inhibitor
6-[4-(N,N-diisopropylcarbamoyl) phenyl]-N-methyl-quinolin-2-one
-
6-[4-[di(propan-2-yl)carbamoyl]phenyl]-3,4-dihydronaphthalene-2-carboxylic acid
-
7-bromo-9,10-dihydrophenanthrene-2-carboxylic acid
-
7-chloro-3,4,4a,9-tetrahydrophenanthrene-2-carboxylic acid
-
7-chloro-9,10-dihydrophenanthrene-2-carboxylic acid
-
7-[(3-methylbut-2-en-1-yl)oxy]-2H-chromen-2-one
-
7-[(E)-2-phenylethenyl]-9,10-dihydrophenanthrene-2-carboxylic acid
-
8-allyl-7-hydroxycoumarin
-
8-bromo-4-methyl-1,4,5,6-tetrahydrobenzo[f]quinolin-3(2H)-one
-
8-chloro-1,2,5,6,6a,7,8,9,10,10a-decahydro-3H-pyrido[1,2-a]quinolin-3-one
-
8-chloro-1,2,5,6,7,8,9,10-octahydro-3H-pyrido[1,2-a]quinolin-3-one
-
8-chloro-1,2,5,6-tetrahydro-3H-pyrido[1,2-a]quinolin-3-one
-
8-chloro-1,4,5,6-tetrahydrobenzo[f]quinolin-3(2H)-one
-
8-chloro-1-methyl-1,2,5,6-tetrahydro-3H-pyrido[1,2-a]quinolin-3-one
-
8-chloro-4,4a,5,6-tetrahydro-3H-pyrido[1,2-a]quinolin-3-one
-
8-chloro-4,6-dimethyl-4,4a,5,6-tetrahydro-3H-pyrido[1,2-a]quinolin-3-one
-
8-chloro-4-methyl-1,4,5,6-tetrahydrobenzo[f]quinolin-3(2H)-one
-
8-chloro-4-methyl-4,4a,5,6-tetrahydro-3H-pyrido[1,2-a]quinolin-3-one
-
8-hydroxyquinoline
-
1 mM, 10% inhibition
8-methyl-1,2,5,6-tetrahydro-3H-pyrido[1,2-a]quinolin-3-one
-
9,10-dihydrophenanthrene-2-carboxylic acid
-
catechin
from green tea, Camellia sinensis, is specific for SRD5alpha1 inhibition
CuSO4
-
1 mM, 95% inhibition
EDTA
-
1 mM, 23% inhibition
estra-4,8-diene-3,17-dione
-
estra-4,9(11)-diene-3,17-dione
-
ethyl 4-[2-[([1-[bis(4-propylphenyl)methyl]-1H-benzimidazol-5-yl]carbonyl)amino]phenoxy]butanoate
FK143
-
dual inhibitor for both isoform 1 and 2
gamma-linolenic acid
a natural product found in oil of evening primrose, Oenothera biennis, oil and borage, Borago officinalis, inhibits SRD5alpha1 and SRD5alpha2
HgCl2
-
1 mM, complete inhibition
iodoacetamide
-
1 mM, 11% inhibition
iodoacetate
-
1 mM, 8% inhibition
KCN
-
1 mM, 24% inhibition
linolenic acid
-
strong inhibition
methyl (1S,9aR,11aS)-9a,11a-dimethyl-7-oxo-2,3,3a,3b,4,5,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-cyclopenta[i]phenanthridine-1-carboxylate
-
methyl(1S,9aR,11aS)-9a,11a-dimethyl-7-oxo-2,3,3a,3b,4,5,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-cyclopenta[i]phenanthridine-1-carboxylate
-
MK386
-
significant decrease in cell proliferation of enzyme-positive prostate cancer cell lines
MK906
-
significant decrease in cell proliferation of enzyme-positive prostate cancer cell lines
MnSO4
-
1 mM, 42% inhibition
Monolinolein
-
strong inhibition
N,N-dicyclohexyl-4-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)benzamide
N-(1,1,1,3,3,3-hexafluorophenylpropyl)-3-oxo-4-aza-5-androst-1-ene-17-carboxamide
i.e. PNU 157706; i.e. PNU 157706
N-(3,3-dimethylbutyl)-N-[(4aR,6aS,7S,11aR)-1,4a,6a-trimethyl-2-oxohexadecahydro-1H-indeno[5,4-f]quinolin-7-yl]formamide
-
N-(3-methylbutan-2-yl)-N-[(4aR,6aS,7S,11aR)-1,4a,6a,10-tetramethyl-2-oxohexadecahydro-1H-indeno[5,4-f]quinolin-7-yl]formamide
-
N-(3-methylbutyl)-N-[(4aR,6aS,7S,11aR)-1,4a,6a-trimethyl-2-oxohexadecahydro-1H-indeno[5,4-f]quinolin-7-yl]formamide
-
N-(4-methoxycyclohexyl)-2-methyl-N-[(4aR,6aS,7S,11aR)-1,4a,6a-trimethyl-2-oxohexadecahydro-1H-indeno[5,4-f]quinolin-7-yl]propanamide
-
N-(dicyclohexyl)acetyl-piperidine-4-(benzylidene-4-carboxylic acid)
-
N-butyl-N-[(4aR,6aS,7S,11aR)-1,4a,6a,10-tetramethyl-2-oxohexadecahydro-1H-indeno[5,4-f]quinolin-7-yl]formamide
-
N-cyclohexyl-N-iodo-4-(2-methoxyquinolin-6-yl)benzamide
-
N-heptyl-N-[(4aR,6aS,7S,11aR)-1,4a,6a-trimethyl-2-oxohexadecahydro-1H-indeno[5,4-f]quinolin-7-yl]formamide
-
N-iodo-4-(2-methoxyquinolin-6-yl)benzamide
-
N-octyl-N-[(4aR,6aS,7S,11aR)-1,4a,6a-trimethyl-2-oxohexadecahydro-1H-indeno[5,4-f]quinolin-7-yl]formamide
-
N-pentyl-N-[(4aR,6aS,7S,11aR)-1,4a,6a,10-tetramethyl-2-oxohexadecahydro-1H-indeno[5,4-f]quinolin-7-yl]formamide
-
N-pentyl-N-[(4aR,6aS,7S,11aR)-1,4a,6a-trimethyl-2-oxohexadecahydro-1H-indeno[5,4-f]quinolin-7-yl]butanamide
-
N-pentyl-N-[(4aR,6aS,7S,11aR)-1,4a,6a-trimethyl-2-oxohexadecahydro-1H-indeno[5,4-f]quinolin-7-yl]formamide
-
N-phenyl-N-[(4aR,6aS,7S,11aR)-1,4a,6a-trimethyl-2-oxohexadecahydro-1H-indeno[5,4-f]quinolin-7-yl]benzamide
-
N-propyl-N-[(4aR,6aS,7S,11aR)-1,4a,6a,10-tetramethyl-2-oxohexadecahydro-1H-indeno[5,4-f]quinolin-7-yl]formamide
-
N-propyl-N-[(4aR,6aS,7S,11aR)-1,4a,6a-trimethyl-2-oxohexadecahydro-1H-indeno[5,4-f]quinolin-7-yl]formamide
-
N-tert-butyl-3-oxoestra-4,9(11)-diene-17-carboxamide
-
N-[1,1,1-trifluoro-2-oxobut-3-yl]-3-oxo-4-aza-5-androst-1-ene-17-carboxamide
NaN3
-
1 mM, 26% inhibition
o-Iodosobenzoate
-
1 mM, complete inhibition
p-chloromercuribenzoate
-
1 mM, 43% inhibition
PNU157706
-
dual inhibitor for both isoform 1 and 2
pregna-4,16-diene-3,6,20-trione
progesterone
-
inhibits the synthesis of 5alpha-dihydrotestosterone by competing with 4-en-3-one function of the testosterone for the 5alpha-reductase enzyme
tricyclo[3.3.1.13,7]dec-2-yl (1S,9aR,11aS)-9a,11a-dimethyl-7-oxo-2,3,3a,3b,4,5,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-cyclopenta[i]phenanthridine-1-carboxylate
-
ZnSO4
-
1 mM, 53% inhibition
[(17beta)-17-(propan-2-ylcarbamoyl)androsta-3,5-dien-3-yl]phosphinic acid
-
[(17beta)-17-(propan-2-ylcarbamoyl)androsta-3,5-dien-3-yl]phosphonic acid
-
[3-fluoro-4-(4-phenoxybenzoyl)phenyl]acetic acid
[3-methyl-4-(4-phenoxybenzoyl)phenyl]acetic acid
[4-(4-phenoxybenzoyl)phenyl]acetic acid
[4-(biphenyl-4-yloxy)phenyl]acetic acid
[4-[4-(4-bromophenoxy)benzoyl]phenyl]acetic acid
(16alpha,17beta)-17-hydroxy-16-methylandrost-4-en-3-one
-
(16alpha,17beta)-17-hydroxy-16-methylandrost-4-en-3-one
-
-
(16beta)-16-methylandrost-4-ene-3,17-dione
-
(16beta)-16-methylandrost-4-ene-3,17-dione
-
-
(17beta)-16-ethyl-17-hydroxyandrost-4-en-3-one
-
(17beta)-16-ethyl-17-hydroxyandrost-4-en-3-one
-
-
(17beta)-17-[3-(4-bromophenyl)-2-oxo-1,3-oxazinan-6-yl]androst-4-en-3-one
-
-
(17beta)-17-[3-(4-bromophenyl)-2-oxo-1,3-oxazinan-6-yl]androst-4-en-3-one
-
(17beta)-17-[3-(4-chlorophenyl)-2-oxo-1,3-oxazinan-6-yl]androst-4-en-3-one
-
-
(17beta)-17-[3-(4-chlorophenyl)-2-oxo-1,3-oxazinan-6-yl]androst-4-en-3-one
-
(17beta)-17-[3-(4-ethoxyphenyl)-2-oxo-1,3-oxazinan-6-yl]androst-4-en-3-one
-
-
(17beta)-17-[3-(4-ethoxyphenyl)-2-oxo-1,3-oxazinan-6-yl]androst-4-en-3-one
-
(17beta)-17-[3-(4-ethylphenyl)-2-oxo-1,3-oxazinan-6-yl]androst-4-en-3-one
-
-
(17beta)-17-[3-(4-ethylphenyl)-2-oxo-1,3-oxazinan-6-yl]androst-4-en-3-one
-
(17beta)-17-[3-(4-methoxyphenyl)-2-oxo-1,3-oxazinan-6-yl]androst-4-en-3-one
-
-
(17beta)-17-[3-(4-methoxyphenyl)-2-oxo-1,3-oxazinan-6-yl]androst-4-en-3-one
-
(17beta)-3-(hydroxymethyl)-N-(propan-2-yl)androsta-3,5-diene-17-carboxamide
weak inhibitor; weak inhibitor
(17beta)-3-(hydroxymethyl)-N-(propan-2-yl)androsta-3,5-diene-17-carboxamide
-
weak inhibitor
(2R,3R,10aR,12aS)-2,10a,12a-trimethyl-1,8-dioxo-3-phenyl-1,2,3,4,4a,4b,8,9,10,10a,10b,11,12,12a-tetradecahydrochrysen-2-yl (2-fluorophenyl)acetate
-
(2R,3R,10aR,12aS)-2,10a,12a-trimethyl-1,8-dioxo-3-phenyl-1,2,3,4,4a,4b,8,9,10,10a,10b,11,12,12a-tetradecahydrochrysen-2-yl (2-fluorophenyl)acetate
-
-
(4aR,5S,6aS,11aR)-N-(diphenylmethyl)-5-hydroxy-1,4a,6a,10-tetramethyl-2-oxo-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
-
(4aR,5S,6aS,11aR)-N-(diphenylmethyl)-5-hydroxy-1,4a,6a,10-tetramethyl-2-oxo-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
-
-
(4aR,5S,6aS,11aR)-N-(diphenylmethyl)-5-hydroxy-4a,6a,10-trimethyl-2-oxo-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
-
(4aR,5S,6aS,11aR)-N-(diphenylmethyl)-5-hydroxy-4a,6a,10-trimethyl-2-oxo-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
-
-
(4aR,6aS,11aR)-N-(2-cyanopropan-2-yl)-1,4a,6a,10-tetramethyl-2-oxo-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
-
(4aR,6aS,11aR)-N-(2-cyanopropan-2-yl)-1,4a,6a,10-tetramethyl-2-oxo-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
-
-
(4aR,6aS,7S,11aR)-1,4a,6a-trimethyl-N-(3-methylbutanoyl)-2-oxo-N-(propan-2-yl)-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
-
(4aR,6aS,7S,11aR)-1,4a,6a-trimethyl-N-(3-methylbutanoyl)-2-oxo-N-(propan-2-yl)-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
-
-
(4aR,6aS,7S,11aR)-1,4a,6a-trimethyl-N-(3-methylbutanoyl)-2-oxo-N-(propan-2-yl)hexadecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
-
(4aR,6aS,7S,11aR)-1,4a,6a-trimethyl-N-(3-methylbutanoyl)-2-oxo-N-(propan-2-yl)hexadecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
-
-
(4aR,6aS,7S,11aR)-4a,6a-dimethyl-N-(3-methylbutanoyl)-2-oxo-N-(propan-2-yl)-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
-
(4aR,6aS,7S,11aR)-4a,6a-dimethyl-N-(3-methylbutanoyl)-2-oxo-N-(propan-2-yl)-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
-
-
(4aR,6aS,7S,11aR)-4a,6a-dimethyl-N-(3-methylbutanoyl)-2-oxo-N-(propan-2-yl)hexadecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
-
(4aR,6aS,7S,11aR)-4a,6a-dimethyl-N-(3-methylbutanoyl)-2-oxo-N-(propan-2-yl)hexadecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
-
-
(4aR,6aS,7S,11aR)-N-(3,3-dimethylpentanoyl)-1,4a,6a-trimethyl-N-(2-methylbutan-2-yl)-2-oxohexadecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
-
(4aR,6aS,7S,11aR)-N-(3,3-dimethylpentanoyl)-1,4a,6a-trimethyl-N-(2-methylbutan-2-yl)-2-oxohexadecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
-
-
(4aR,6aS,7S,11aR)-N-(diphenylmethyl)-1,4a,6a-trimethyl-2,5-dioxohexadecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
-
(4aR,6aS,7S,11aR)-N-(diphenylmethyl)-1,4a,6a-trimethyl-2,5-dioxohexadecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
-
-
(4aR,6aS,7S,11aR)-N-(diphenylmethyl)-4a,6a-dimethyl-2,5-dioxo-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
-
(4aR,6aS,7S,11aR)-N-(diphenylmethyl)-4a,6a-dimethyl-2,5-dioxo-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
-
-
(4aR,6aS,7S,11aR)-N-(diphenylmethyl)-4a,6a-dimethyl-2,5-dioxohexadecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
-
(4aR,6aS,7S,11aR)-N-(diphenylmethyl)-4a,6a-dimethyl-2,5-dioxohexadecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
-
-
(4aR,6aS,7S,11aR)-N-cyclohexyl-N-(cyclohexylacetyl)-1,4a,6a-trimethyl-2-oxohexadecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
-
(4aR,6aS,7S,11aR)-N-cyclohexyl-N-(cyclohexylacetyl)-1,4a,6a-trimethyl-2-oxohexadecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
-
-
(5alpha,6alpha)-20-oxo-5,6-epoxypregn-16-en-3-yl acetate
-
(5alpha,6alpha)-20-oxo-5,6-epoxypregn-16-en-3-yl acetate
-
-
(S)-4-[1-[4-[[1-(4-isobutylphenyl)butyl]oxy]benzoyl]indolizin-3-yl]-butyric acid
-
(S)-4-[1-[4-[[1-(4-isobutylphenyl)butyl]oxy]benzoyl]indolizin-3-yl]-butyric acid
-
-
(S)-4-[1-[4-[[1-(4-isobutylphenyl)butyl]oxy]benzoyl]indolizin-3-yl]butyric acid
-
(S)-4-[1-[4-[[1-(4-isobutylphenyl)butyl]oxy]benzoyl]indolizin-3-yl]butyric acid
-
-
1-(3-carboxypropyl)-4-[4-([[3-(2-methylpropyl)phenyl][4-(2-methylpropyl)phenyl]methyl]amino)benzoyl]-1H-pyrrole-3-carboxylic acid
-
1-(3-carboxypropyl)-4-[4-([[3-(2-methylpropyl)phenyl][4-(2-methylpropyl)phenyl]methyl]amino)benzoyl]-1H-pyrrole-3-carboxylic acid
-
-
16,16-dimethylandrost-4-ene-3,17-dione
-
16,16-dimethylandrost-4-ene-3,17-dione
-
-
16-ethyl-17beta-hydroxy-4-estren-3-one
i.e. TSAA-291; i.e. TSAA-291
16-ethyl-17beta-hydroxy-4-estren-3-one
-
i.e. TSAA-291, with purified nuclei from rat prostatic tissues
17beta-N,N-diethylcarbamoyl-4-methyl-4-aza-5alpha-androstan-3-one
-
17beta-N,N-diethylcarbamoyl-4-methyl-4-aza-5alpha-androstan-3-one
-
-
2',3'-tetrahydrofuran-2'-spiro-17-(6-methylene-4-androsten-3-one)
i.e. L612,710; i.e. L612,710
2',3'-tetrahydrofuran-2'-spiro-17-(6-methylene-4-androsten-3-one)
-
i.e. L612,710
3,20-dioxopregna-4,6-dien-17-yl 4-bromobenzoate
-
3,20-dioxopregna-4,6-dien-17-yl 4-bromobenzoate
-
-
3,20-dioxopregna-4,6-dien-17-yl 4-fluorobenzoate
-
3,20-dioxopregna-4,6-dien-17-yl 4-fluorobenzoate
-
-
3,20-dioxopregna-4,6-dien-17-yl benzoate
-
3,20-dioxopregna-4,6-dien-17-yl benzoate
-
-
3-(2,4-dimethoxyphenyl)-5-methoxy-8,8-dimethyl-4H,8H-pyrano[2,3-f]chromen-4-one
-
3-(2,4-dimethoxyphenyl)-5-methoxy-8,8-dimethyl-4H,8H-pyrano[2,3-f]chromen-4-one
-
-
3-chloro-4-([1-(4-phenoxybenzyl)indolin-5-yl]oxy)benzoic acid
i.e. YM-36117; i.e. YM-36117
3-chloro-4-([1-(4-phenoxybenzyl)indolin-5-yl]oxy)benzoic acid
-
i.e. YM-36117
3-[2,4-bis(benzyloxy)phenyl]-5-methoxy-8,8-dimethyl-4H,8H-pyrano[2,3-f]chromen-4-one
-
3-[2,4-bis(benzyloxy)phenyl]-5-methoxy-8,8-dimethyl-4H,8H-pyrano[2,3-f]chromen-4-one
-
-
3-[2,4-bis(benzyloxy)phenyl]-5-methoxy-8,8-dimethyl-8,9-dihydro-4H,10H-pyrano[2,3-f]chromene-4,10-dione
-
3-[2,4-bis(benzyloxy)phenyl]-5-methoxy-8,8-dimethyl-8,9-dihydro-4H,10H-pyrano[2,3-f]chromene-4,10-dione
-
-
3-[4-(4-phenoxybenzoyl)phenyl]acrylic acid
-
pH 5.5, isoform 2, 50% inhibition at 0.00047 mM, not inhibitory to isoform 1
3-[4-(4-phenoxybenzoyl)phenyl]acrylic acid
-
pH 5.5, 63% inhibition at 0.01 mM, pH 6.6, 61% inhibition at 0.01 mM
4'-(tricyclo[3.3.1.13,7]dec-2-ylcarbamoyl)biphenyl-4-carboxylic acid
-
4'-(tricyclo[3.3.1.13,7]dec-2-ylcarbamoyl)biphenyl-4-carboxylic acid
-
-
4-(2-[1-(4,4'-dipropylbenzhydryl)indole-5-carboxamido]phenoxy)butyric acid
-
4-(2-[1-(4,4'-dipropylbenzhydryl)indole-5-carboxamido]phenoxy)butyric acid
-
-
4-(4-phenoxybenzoyl)benzoic acid
-
pH 5.5, isoform 2, 50% inhibition at 0.000053 mM, not inhibitory to isoform 1
4-(4-phenoxybenzoyl)benzoic acid
-
pH 5.5, 33% inhibition at 0.01 mM, pH 6.6, 53% inhibition at 0.01 mM
4-cyanoprogesterone
-
4-[(1-benzyl-1H-indol-5-yl)oxy]-3-chlorobenzoic acid
-
4-[(1-benzyl-1H-indol-5-yl)oxy]-3-chlorobenzoic acid
-
-
4-[1-(6,6-dimethyl-6H-dibenzo[b,d]pyran-3-yl)methylindol-3-yl]-butyric acid
i.e. FR119680; i.e. FR119680
4-[1-(6,6-dimethyl-6H-dibenzo[b,d]pyran-3-yl)methylindol-3-yl]-butyric acid
-
i.e. FR119680
4-[2-(1-methyl-6-oxopiperidin-3-yl)ethyl]-N,N-di(propan-2-yl)benzamide
-
4-[2-(1-methyl-6-oxopiperidin-3-yl)ethyl]-N,N-di(propan-2-yl)benzamide
-
-
4-[2-(6-[[bis(4-fluorophenyl)methyl]carbamoyl]-1-benzofuran-2-yl)phenoxy]butanoic acid
-
4-[2-(6-[[bis(4-fluorophenyl)methyl]carbamoyl]-1-benzofuran-2-yl)phenoxy]butanoic acid
-
-
4-[3-(1-methyl-6-oxopiperidin-3-yl)butan-2-yl]-N,N-di(propan-2-yl)benzamide
-
4-[3-(1-methyl-6-oxopiperidin-3-yl)butan-2-yl]-N,N-di(propan-2-yl)benzamide
-
-
4-[3-(benzyloxy)benzoyl]benzoic acid
-
pH 5.5, isoform 2, 50% inhibition at 0.000131 mM, not inhibitory to isoform 1
4-[3-(benzyloxy)benzoyl]benzoic acid
-
pH 5.5, 55% inhibition at 0.01 mM, pH 6.6, 35% inhibition at 0.01 mM
4-[3-ethyl-4-[4-([[3-(2-methylpropyl)phenyl][4-(2-methylpropyl)phenyl]methyl]amino)benzoyl]-1H-pyrrol-1-yl]butanoic acid
-
4-[3-ethyl-4-[4-([[3-(2-methylpropyl)phenyl][4-(2-methylpropyl)phenyl]methyl]amino)benzoyl]-1H-pyrrol-1-yl]butanoic acid
-
-
4-[3-[3-([[3-(2-methylpropyl)phenyl][4-(2-methylpropyl)phenyl]methyl]amino)benzoyl]-4-(propan-2-yl)-1H-pyrrol-1-yl]butanoic acid
-
4-[3-[3-([[3-(2-methylpropyl)phenyl][4-(2-methylpropyl)phenyl]methyl]amino)benzoyl]-4-(propan-2-yl)-1H-pyrrol-1-yl]butanoic acid
-
-
4-[3-[3-[bis (4-isobutylphenyl)methylamino]benzoyl]-lH-indol-l-yl] butyric acid
i.e. FK-143
4-[3-[3-[bis (4-isobutylphenyl)methylamino]benzoyl]-lH-indol-l-yl] butyric acid
-
i.e. FK-143
4-[3-[3-[bis(4-isobutylphenyl)methylamino]benzoyl]-lH-indol-l-yl]butyric acid
-
4-[3-[3-[bis(4-isobutylphenyl)methylamino]benzoyl]-lH-indol-l-yl]butyric acid
-
-
4-[3-[4-([[3-(2-methylpropyl)phenyl][4-(2-methylpropyl)phenyl]methyl]amino)benzoyl]-1H-pyrrol-1-yl]butanoic acid
-
4-[3-[4-([[3-(2-methylpropyl)phenyl][4-(2-methylpropyl)phenyl]methyl]amino)benzoyl]-1H-pyrrol-1-yl]butanoic acid
-
-
4-[3-[4-([[3-(2-methylpropyl)phenyl][4-(2-methylpropyl)phenyl]methyl]amino)benzoyl]-4-(propan-2-yl)-1H-pyrrol-1-yl]butanoic acid
-
4-[3-[4-([[3-(2-methylpropyl)phenyl][4-(2-methylpropyl)phenyl]methyl]amino)benzoyl]-4-(propan-2-yl)-1H-pyrrol-1-yl]butanoic acid
-
-
4-[4-(benzyloxy)benzoyl]benzoic acid
-
pH 5.5, isoform 2, 50% inhibition at 0.000119 mM, not inhibitory to isoform 1
4-[4-(benzyloxy)benzoyl]benzoic acid
-
pH 5.5, 0.01 mM, 45% inhibition at 0.01 mM, pH 6.6, 64% inhibition at 0.01 mM
4-[4-(tricyclo[3.3.1.13,7]dec-2-ylcarbamoyl)phenoxy]benzoic acid
-
4-[4-(tricyclo[3.3.1.13,7]dec-2-ylcarbamoyl)phenoxy]benzoic acid
-
-
4-[[1-(2-propylpentanoyl)piperidin-4-ylidene]methyl]benzoic acid
-
4-[[1-(2-propylpentanoyl)piperidin-4-ylidene]methyl]benzoic acid
-
type II isozyme
4-[[1-(biphenyl-4-ylcarbamoyl)piperidin-4-ylidene]methyl]benzoic acid
-
4-[[1-(biphenyl-4-ylcarbamoyl)piperidin-4-ylidene]methyl]benzoic acid
-
type II isozyme; type I isozyme
4-[[1-(dicyclohexylacetyl)piperidin-4-ylidene]methyl]benzoic acid
-
4-[[1-(dicyclohexylacetyl)piperidin-4-ylidene]methyl]benzoic acid
-
type II isozyme; type I isozyme
4-[[1-(diphenylacetyl)piperidin-4-ylidene]methyl]benzoic acid
-
4-[[1-(diphenylacetyl)piperidin-4-ylidene]methyl]benzoic acid
-
type II isozyme; type I isozyme
5-(2-ethyl-3-[3-[(4-hexylundecyl)amino]benzoyl]-1H-pyrrol-1-yl)pentanoate
-
5-(2-ethyl-3-[3-[(4-hexylundecyl)amino]benzoyl]-1H-pyrrol-1-yl)pentanoate
-
-
6,20-dioxopregna-4,16-dien-3-yl acetate
-
6,20-dioxopregna-4,16-dien-3-yl acetate
-
-
6,20-dioxopregna-4,16-dien-3-yl benzoate
-
6,20-dioxopregna-4,16-dien-3-yl benzoate
-
-
6-bromo-3,20-dioxopregna-4,6-dien-17-yl acetate
i.e. ONO-3806; i.e. ONO-3806
6-bromo-3,20-dioxopregna-4,6-dien-17-yl acetate
-
-
6-chloro-3,20-dioxopregna-4,6-dien-17-yl 4-bromobenzoate
-
6-chloro-3,20-dioxopregna-4,6-dien-17-yl 4-bromobenzoate
-
-
6-chloro-3,20-dioxopregna-4,6-dien-17-yl 4-fluorobenzoate
-
6-chloro-3,20-dioxopregna-4,6-dien-17-yl 4-fluorobenzoate
-
-
6-chloro-3,20-dioxopregna-4,6-dien-17-yl benzoate
-
6-chloro-3,20-dioxopregna-4,6-dien-17-yl benzoate
-
-
6-hydroxy-9,10-dimethoxy-3,3-dimethyl-3H-chromeno[3,4-b]pyrano[2,3-h]chromen-7(13H)-one
-
6-hydroxy-9,10-dimethoxy-3,3-dimethyl-3H-chromeno[3,4-b]pyrano[2,3-h]chromen-7(13H)-one
-
-
androst-4-ene-3,17-dione
-
androst-4-ene-3,17-dione
-
-
dutasteride
-
-
dutasteride
-
inhibition of both isoform 1 and 2
dutasteride
-
inhibits type 1 5alpha-reductase
dutasteride
SRD5alpha2 and SRD5alpha1 both respond similarly to dutasteride
dutasteride
inhibits 5alphaR1 and 5alphaR2; inhibits 5alphaR1 and 5alphaR2
dutasteride
i.e. 17beta-N-(2,5-bis(trifluoromethyl)-phenyl)-3-oxo-4-aza-5alpha-androst-1-ene-17-carboxamide, a competitive inhibitor of both 5alpha-reductase type I and type II isozymes, reduces DHT levels over 90% following 1 year of oral administration; i.e. 17beta-N-(2,5-bis(trifluoromethyl)-phenyl)-3-oxo-4-aza-5alpha-androst-1-ene-17-carboxamide, a competitive inhibitor of both 5alpha-reductase type I and type II isozymes, reduces DHT levels over 90% following 1 year of oral administration
dutasteride
-
dual inhibitor for both isoform 1 and 2
ethyl 4-[2-[([1-[bis(4-propylphenyl)methyl]-1H-benzimidazol-5-yl]carbonyl)amino]phenoxy]butanoate
-
ethyl 4-[2-[([1-[bis(4-propylphenyl)methyl]-1H-benzimidazol-5-yl]carbonyl)amino]phenoxy]butanoate
-
-
finasteride
-
SRD5alpha2 is more sensitive to finasteride than SRD5alpha1
finasteride
-
pH 5.5, isoform 2, 50% inhibition at 0.000005 mM, isoform 1, 50% inhibition at 0.051 mM
finasteride
-
inhibits type 2 5alpha-reductase
finasteride
SRD5alpha2 is more sensitive to finasteride than SRD5alpha1
finasteride
i.e. 17beta-(N-tert-butylcarbamoyl)-4-aza-5alpha-androst-1-en-3-one, decreases the prostatic DHT level by 70-90% and reduces the prostatic size, inhibition mechanism, detailed overview; i.e. 17beta-(N-tert-butylcarbamoyl)-4-aza-5alpha-androst-1-en-3-one, decreases the prostatic dihydrotestosterone level by 70-90% and reduces the prostatic size, inhibition mechanism, detailed overview
finasteride
-
i.e. 17beta-(N-tert-butylcarbamoyl)-4-aza-5alpha-androst-1-en-3-one or MK-906. A competitive inhibitor of 5alpha-reductase type II with 10fold higher affinity than type I due to formation of stable complex with enzyme
finasteride
-
pH 5.5, 50% inhibition at 0.000011 mM, pH 6.6, 50% inhibition at 0.00001 mM
finasteride
-
5mg/kg, chronic finasteride administration effectively blocks development of tolerance and dependence to morphine
finasteride
-
both SRD5alpha subtypes 1 and 2 are inhibited
kaempferol
-
inhibition of both isoforms I and II
N,N-dicyclohexyl-4-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)benzamide
-
N,N-dicyclohexyl-4-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)benzamide
-
-
N-[1,1,1-trifluoro-2-oxobut-3-yl]-3-oxo-4-aza-5-androst-1-ene-17-carboxamide
-
N-[1,1,1-trifluoro-2-oxobut-3-yl]-3-oxo-4-aza-5-androst-1-ene-17-carboxamide
-
-
pregna-4,16-diene-3,6,20-trione
-
pregna-4,16-diene-3,6,20-trione
-
-
Strogen forte
-
standardized extract of the plant Sabalis serrulata, 0.245 mg/ml result in 50% enzyme inhibition
-
Strogen forte
-
standardized extract of the plant Sabalis serrulata, 0.385 mg/ml result in 50% enzyme inhibition
-
[3-fluoro-4-(4-phenoxybenzoyl)phenyl]acetic acid
-
pH 5.5, isoform 2, 50% inhibition at 0.000045 mM, not inhibitory to isoform 1
[3-fluoro-4-(4-phenoxybenzoyl)phenyl]acetic acid
-
pH 5.5, 73% inhibition at 0.01 mM, pH 6.6, 57% inhibition at 0.01 mM
[3-methyl-4-(4-phenoxybenzoyl)phenyl]acetic acid
-
pH 5.5, isoform 2, 50% inhibition at 0.000027 mM, not inhibitory to isoform 1
[3-methyl-4-(4-phenoxybenzoyl)phenyl]acetic acid
-
[3-methyl-4-(4-phenoxybenzoyl)phenyl]acetic acid
-
pH 5.5, 78% inhibition at 0.01 mM, pH 6.6, 50% inhibition at 0.00145 mM
[4-(4-phenoxybenzoyl)phenyl]acetic acid
-
pH 5.5, isoform 2, 50% inhibition at 0.000023 mM, not inhibitory to isoform 1
[4-(4-phenoxybenzoyl)phenyl]acetic acid
-
[4-(4-phenoxybenzoyl)phenyl]acetic acid
-
pH 5.5, 77% inhibition at 0.01 mM, pH 6.6, 42% inhibition at 0.01 mM
[4-(biphenyl-4-yloxy)phenyl]acetic acid
-
[4-(biphenyl-4-yloxy)phenyl]acetic acid
-
-
[4-[4-(4-bromophenoxy)benzoyl]phenyl]acetic acid
-
pH 5.5, isoform 2, 50% inhibition at 0.000005 mM, not inhibitory to isoform 1
[4-[4-(4-bromophenoxy)benzoyl]phenyl]acetic acid
-
additional information
-
4-aza-3-oxo-1-ene compounds are the major class of synthetic SRD5alpha inhibitors, they require a structure similar to 3-oxo-4-ene with a secondary 17beta-substituent to successfully bind to the SRD5alpha-NADPH or SRD5alpha-NADP+ complexes
-
additional information
-
4-aza-3-oxo-1-ene compounds are the major class of synthetic SRD5alpha inhibitors, they require a structure similar to 3-oxo-4-ene with a secondary 17beta-substituent to successfully bind to the SRD5alpha-NADPH or SRD5alpha-NADP+ complexes
-
additional information
-
4-aza-3-oxo-1-ene compounds are the major class of synthetic SRD5alpha inhibitors, they require a structure similar to 3-oxo-4-ene with a secondary 17beta-substituent to successfully bind to the SRD5alpha-NADPH or SRD5alpha-NADP+ complexes
-
additional information
4-aza-3-oxo-1-ene compounds are the major class of synthetic SRD5alpha inhibitors, they require a structure similar to 3-oxo-4-ene with a secondary 17beta-substituent to successfully bind to the SRD5alpha-NADPH or SRD5alpha-NADP+ complexes
-
additional information
-
synthesis, enzyme inhibitory, and cell cytotoxicity of pregnan compounds, IC50 values for growth inhibition, overview
-
additional information
no inhibition of 5alphaR1 by tetracycline
-
additional information
no inhibition of 5alphaR1 by tetracycline
-
additional information
steroidal and non-steroidal 5alpha-reductase inhibitors as they inhibit the conversion of testosterone to 5alpha-dihydrotestosterone, detailed overview. 4-Aza, 6-aza and charged 3-substituents derivatives are highly selective for type II enzyme. Potent inhibitors of steroid 5alpha-reductase are found among the transition state analogues as molecules mimicking the transition state of the enzymatic processes exhibit a greater binding to the enzyme and hence produce greater inhibition. The enzyme 5alpha-reductase binds the 3-keto-DELTA4 steroids in such a way that the carbonyl group is brought into vicinity of a positively charged centre on the enzyme whereby the conjugated ketone becomes activated. Poor inhibition by (4aS,6aS,7S,11aS)-7-hydroxy-4a,6a-dimethylhexadecahydro-2H-indeno[4,5-h]isoquinolin-2-one, (4aS,6aS,7S,11aS)-4a,6a-dimethylhexadecahydro-1H-indeno[4,5-h]isoquinolin-7-ol, and (4aS,6aS,7S,11aR)-7-hydroxy-4a,6a-dimethyl-1,2,4,4a,5,6,6a,7,8,9,9a,10,11,11a-tetradecahydro-3H-indeno[5,4-f]isoquinolin-3-one. No inhibition (17E)-17-(hydroxyimino)androst-5-en-3-ol, (20Z)-20-(hydroxyimino)pregn-5-en-3-ol, (20Z)-20-(hydroxyimino)pregna-5,16-dien-3-ol, 20-(hydroxyimino)pregna-5,14-dien-3-ol, and 20-(hydroxyimino)pregna-5,14,16-trien-3-ol, and by 2-[4-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenoxy]-N-(propan-2-yl)acetamide, 2-[4-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenoxy]-N-(prop-2-en-1-yl)acetamide, 2-[4-(1-methyl-6-oxopiperidin-3-yl)phenoxy]-N-(propan-2-yl)acetamide, 2-[4-(1,2-dimethyl-6-oxo-1,2,3,6-tetrahydropyridin-3-yl)phenoxy]-N-(propan-2-yl)acetamide, 1-methyl-5-[4-(phenylacetyl)phenyl]pyridin-2(1H)-one, 2-[[16-(acetylsulfanyl)hexadecanoyl]amino]ethyl (4Z)-6-([[4-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenoxy]acetyl]amino)hex-4-enoate, and 3-(2-[[16-(acetylsulfanyl)hexadecanoyl]amino]ethoxy)propyl (4Z)-6-([[4-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenoxy]acetyl]amino)hex-4-enoate, as well as 8-chloro-1,2,5,6,7,8,9,10-octahydro-3H-pyrido[1,2-a]quinolin-3-one and 8-chloro-1,2,5,6,6a,7,8,9,10,10a-decahydro-3H-pyrido[1,2-a]quinolin-3-one; steroidal and non-steroidal 5alpha-reductase inhibitors as they inhibit the conversion of testosterone to 5alpha-dihydrotestosterone, detailed overview. Inhibitors with 4-methyl-4-aza functionality are very potent for type I enzyme. Potent inhibitors of steroid 5alpha-reductase are found among the transition state analogues as molecules mimicking the transition state of the enzymatic processes exhibit a greater binding to the enzyme and hence produce greater inhibition. The enzyme 5alpha-reductase binds the 3-keto-DELTA4 steroids in such a way that the carbonyl group is brought into vicinity of a positively charged centre on the enzyme whereby the conjugated ketone becomes activated. Poor inhibition by (4aS,6aS,7S,11aS)-7-hydroxy-4a,6a-dimethylhexadecahydro-2H-indeno[4,5-h]isoquinolin-2-one, (4aS,6aS,7S,11aS)-4a,6a-dimethylhexadecahydro-1H-indeno[4,5-h]isoquinolin-7-ol, (4aS,6aS,7S,11aR)-7-hydroxy-4a,6a-dimethyl-1,2,4,4a,5,6,6a,7,8,9,9a,10,11,11a-tetradecahydro-3H-indeno[5,4-f]isoquinolin-3-one, and (4aS,6aS,7S,11aR)-4a,6a-dimethyl-2,3,4,4a,5,6,6a,7,8,9,9a,10,11,11a-tetradecahydro-1H-indeno[5,4-f]isoquinolin-7-ol. No inhibition by (17E)-17-(hydroxyimino)androst-5-en-3-ol, (20Z)-20-(hydroxyimino)pregn-5-en-3-ol, (20Z)-20-(hydroxyimino)pregna-5,16-dien-3-ol, 20-(hydroxyimino)pregna-5,14-dien-3-ol, and 20-(hydroxyimino)pregna-5,14,16-trien-3-ol
-
additional information
steroidal and non-steroidal 5alpha-reductase inhibitors as they inhibit the conversion of testosterone to 5alpha-dihydrotestosterone, detailed overview. 4-Aza, 6-aza and charged 3-substituents derivatives are highly selective for type II enzyme. Potent inhibitors of steroid 5alpha-reductase are found among the transition state analogues as molecules mimicking the transition state of the enzymatic processes exhibit a greater binding to the enzyme and hence produce greater inhibition. The enzyme 5alpha-reductase binds the 3-keto-DELTA4 steroids in such a way that the carbonyl group is brought into vicinity of a positively charged centre on the enzyme whereby the conjugated ketone becomes activated. Poor inhibition by (4aS,6aS,7S,11aS)-7-hydroxy-4a,6a-dimethylhexadecahydro-2H-indeno[4,5-h]isoquinolin-2-one, (4aS,6aS,7S,11aS)-4a,6a-dimethylhexadecahydro-1H-indeno[4,5-h]isoquinolin-7-ol, and (4aS,6aS,7S,11aR)-7-hydroxy-4a,6a-dimethyl-1,2,4,4a,5,6,6a,7,8,9,9a,10,11,11a-tetradecahydro-3H-indeno[5,4-f]isoquinolin-3-one. No inhibition (17E)-17-(hydroxyimino)androst-5-en-3-ol, (20Z)-20-(hydroxyimino)pregn-5-en-3-ol, (20Z)-20-(hydroxyimino)pregna-5,16-dien-3-ol, 20-(hydroxyimino)pregna-5,14-dien-3-ol, and 20-(hydroxyimino)pregna-5,14,16-trien-3-ol, and by 2-[4-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenoxy]-N-(propan-2-yl)acetamide, 2-[4-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenoxy]-N-(prop-2-en-1-yl)acetamide, 2-[4-(1-methyl-6-oxopiperidin-3-yl)phenoxy]-N-(propan-2-yl)acetamide, 2-[4-(1,2-dimethyl-6-oxo-1,2,3,6-tetrahydropyridin-3-yl)phenoxy]-N-(propan-2-yl)acetamide, 1-methyl-5-[4-(phenylacetyl)phenyl]pyridin-2(1H)-one, 2-[[16-(acetylsulfanyl)hexadecanoyl]amino]ethyl (4Z)-6-([[4-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenoxy]acetyl]amino)hex-4-enoate, and 3-(2-[[16-(acetylsulfanyl)hexadecanoyl]amino]ethoxy)propyl (4Z)-6-([[4-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenoxy]acetyl]amino)hex-4-enoate, as well as 8-chloro-1,2,5,6,7,8,9,10-octahydro-3H-pyrido[1,2-a]quinolin-3-one and 8-chloro-1,2,5,6,6a,7,8,9,10,10a-decahydro-3H-pyrido[1,2-a]quinolin-3-one; steroidal and non-steroidal 5alpha-reductase inhibitors as they inhibit the conversion of testosterone to 5alpha-dihydrotestosterone, detailed overview. Inhibitors with 4-methyl-4-aza functionality are very potent for type I enzyme. Potent inhibitors of steroid 5alpha-reductase are found among the transition state analogues as molecules mimicking the transition state of the enzymatic processes exhibit a greater binding to the enzyme and hence produce greater inhibition. The enzyme 5alpha-reductase binds the 3-keto-DELTA4 steroids in such a way that the carbonyl group is brought into vicinity of a positively charged centre on the enzyme whereby the conjugated ketone becomes activated. Poor inhibition by (4aS,6aS,7S,11aS)-7-hydroxy-4a,6a-dimethylhexadecahydro-2H-indeno[4,5-h]isoquinolin-2-one, (4aS,6aS,7S,11aS)-4a,6a-dimethylhexadecahydro-1H-indeno[4,5-h]isoquinolin-7-ol, (4aS,6aS,7S,11aR)-7-hydroxy-4a,6a-dimethyl-1,2,4,4a,5,6,6a,7,8,9,9a,10,11,11a-tetradecahydro-3H-indeno[5,4-f]isoquinolin-3-one, and (4aS,6aS,7S,11aR)-4a,6a-dimethyl-2,3,4,4a,5,6,6a,7,8,9,9a,10,11,11a-tetradecahydro-1H-indeno[5,4-f]isoquinolin-7-ol. No inhibition by (17E)-17-(hydroxyimino)androst-5-en-3-ol, (20Z)-20-(hydroxyimino)pregn-5-en-3-ol, (20Z)-20-(hydroxyimino)pregna-5,16-dien-3-ol, 20-(hydroxyimino)pregna-5,14-dien-3-ol, and 20-(hydroxyimino)pregna-5,14,16-trien-3-ol
-
additional information
-
steroidal and non-steroidal 5alpha-reductase inhibitors as they inhibit the conversion of testosterone to 5alpha-dihydrotestosterone, detailed overview. 4-Aza, 6-aza and charged 3-substituents derivatives are highly selective for type II enzyme. Potent inhibitors of steroid 5alpha-reductase are found among the transition state analogues as molecules mimicking the transition state of the enzymatic processes exhibit a greater binding to the enzyme and hence produce greater inhibition. The enzyme 5alpha-reductase binds the 3-keto-DELTA4 steroids in such a way that the carbonyl group is brought into vicinity of a positively charged centre on the enzyme whereby the conjugated ketone becomes activated. Poor inhibition by (4aS,6aS,7S,11aS)-7-hydroxy-4a,6a-dimethylhexadecahydro-2H-indeno[4,5-h]isoquinolin-2-one, (4aS,6aS,7S,11aS)-4a,6a-dimethylhexadecahydro-1H-indeno[4,5-h]isoquinolin-7-ol, and (4aS,6aS,7S,11aR)-7-hydroxy-4a,6a-dimethyl-1,2,4,4a,5,6,6a,7,8,9,9a,10,11,11a-tetradecahydro-3H-indeno[5,4-f]isoquinolin-3-one. No inhibition (17E)-17-(hydroxyimino)androst-5-en-3-ol, (20Z)-20-(hydroxyimino)pregn-5-en-3-ol, (20Z)-20-(hydroxyimino)pregna-5,16-dien-3-ol, 20-(hydroxyimino)pregna-5,14-dien-3-ol, and 20-(hydroxyimino)pregna-5,14,16-trien-3-ol, and by 2-[4-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenoxy]-N-(propan-2-yl)acetamide, 2-[4-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenoxy]-N-(prop-2-en-1-yl)acetamide, 2-[4-(1-methyl-6-oxopiperidin-3-yl)phenoxy]-N-(propan-2-yl)acetamide, 2-[4-(1,2-dimethyl-6-oxo-1,2,3,6-tetrahydropyridin-3-yl)phenoxy]-N-(propan-2-yl)acetamide, 1-methyl-5-[4-(phenylacetyl)phenyl]pyridin-2(1H)-one, 2-[[16-(acetylsulfanyl)hexadecanoyl]amino]ethyl (4Z)-6-([[4-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenoxy]acetyl]amino)hex-4-enoate, and 3-(2-[[16-(acetylsulfanyl)hexadecanoyl]amino]ethoxy)propyl (4Z)-6-([[4-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenoxy]acetyl]amino)hex-4-enoate, as well as 8-chloro-1,2,5,6,7,8,9,10-octahydro-3H-pyrido[1,2-a]quinolin-3-one and 8-chloro-1,2,5,6,6a,7,8,9,10,10a-decahydro-3H-pyrido[1,2-a]quinolin-3-one; steroidal and non-steroidal 5alpha-reductase inhibitors as they inhibit the conversion of testosterone to 5alpha-dihydrotestosterone, detailed overview. Inhibitors with 4-methyl-4-aza functionality are very potent for type I enzyme. Potent inhibitors of steroid 5alpha-reductase are found among the transition state analogues as molecules mimicking the transition state of the enzymatic processes exhibit a greater binding to the enzyme and hence produce greater inhibition. The enzyme 5alpha-reductase binds the 3-keto-DELTA4 steroids in such a way that the carbonyl group is brought into vicinity of a positively charged centre on the enzyme whereby the conjugated ketone becomes activated. Poor inhibition by (4aS,6aS,7S,11aS)-7-hydroxy-4a,6a-dimethylhexadecahydro-2H-indeno[4,5-h]isoquinolin-2-one, (4aS,6aS,7S,11aS)-4a,6a-dimethylhexadecahydro-1H-indeno[4,5-h]isoquinolin-7-ol, (4aS,6aS,7S,11aR)-7-hydroxy-4a,6a-dimethyl-1,2,4,4a,5,6,6a,7,8,9,9a,10,11,11a-tetradecahydro-3H-indeno[5,4-f]isoquinolin-3-one, and (4aS,6aS,7S,11aR)-4a,6a-dimethyl-2,3,4,4a,5,6,6a,7,8,9,9a,10,11,11a-tetradecahydro-1H-indeno[5,4-f]isoquinolin-7-ol. No inhibition by (17E)-17-(hydroxyimino)androst-5-en-3-ol, (20Z)-20-(hydroxyimino)pregn-5-en-3-ol, (20Z)-20-(hydroxyimino)pregna-5,16-dien-3-ol, 20-(hydroxyimino)pregna-5,14-dien-3-ol, and 20-(hydroxyimino)pregna-5,14,16-trien-3-ol
-
additional information
-
design and optimization of steroidal structure as 5alpha-reductase inhibitors, rationalizing the molecular properties and 5alpha-reductase inhibitory activities, three-dimensional quantitative structure-activity relationship, 3D-QSAR, study and modeling, overview
-
additional information
-
green tea seed extract hydrolysate shows a good inhibition effect on HEK 293 cell lines on both type 1 and type 2 5alpha-reductase
-
additional information
-
hot water extract and 20% (v/v) ethanol extract of Curcuma longa significantly inhibit 5-alpha reductase activity
-
additional information
-
4-aza-3-oxo-1-ene compounds are the major class of synthetic SRD5alpha inhibitors, they require a structure similar to 3-oxo-4-ene with a secondary 17beta-substituent to successfully bind to the SRD5alpha-NADPH or SRD5alpha-NADP+ complexes
-
additional information
-
expression of isozyme 5alpha-R1 is inhibited by testosterone and dihydrotestosterone
-
additional information
-
screening of biologically active constituents from Brassica rapa pollen in supercritical CO2 fluid extract, overview. No inhibition by 24-methylenecholesterol linolenate, cycloeucalenol linolenate, 24-methylenecholesterol palmitate, cycloeucalenol, pollinastanol, 24-methylenecholesterol, palmitic acid, and monopalmitin
-
additional information
-
4-aza-3-oxo-1-ene compounds are the major class of synthetic SRD5alpha inhibitors, they require a structure similar to 3-oxo-4-ene with a secondary 17beta-substituent to successfully bind to the SRD5alpha-NADPH or SRD5alpha-NADP+ complexes
-
additional information
-
hot water extract and 20% (v/v) ethanol extract of Curcuma longa significantly inhibit 5-alpha reductase activity
-
additional information
-
4-aza-3-oxo-1-ene compounds are the major class of synthetic SRD5alpha inhibitors, they require a structure similar to 3-oxo-4-ene with a secondary 17beta-substituent to successfully bind to the SRD5alpha-NADPH or SRD5alpha-NADP+ complexes
-